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CHAPTER I 
INTRODUCTION 
Lifetime Prevalence, Presentation and Prognosis of Post Traumatic Stress Disorder 
Post Traumatic Stress Disorder (PTSD) is a mental disorder with a life time prevalence of 
6.8%-8.0% of the population (Kessler, Berglund et al. 2005, Alegria, Jackson et al. 2016). 
Categorized until recently as a subclass of anxiety disorder, PTSD is now listed in the Diagnostic 
Statistical Manual V (DSMV) as a stress related, post trauma phenomenon in which 69.7% of 
those diagnosed  experience severe to moderate impairment of daily life (Kessler, Chiu et al. 2005, 
Alegria, Jackson et al. 2016). During any given year it is estimated that approximately 3.6-8% of 
adults (approximately 13.3- 24.4 million) currently meet the diagnostic criteria stated in the DSMV 
for the PTSD (Kilpatrick, Resnick et al. 2013, Alegria, Jackson et al. 2016). Women are diagnosed 
with PTSD at a higher rate than men at a rate of 10.4% and 5% respectively (Arnatt 2015, Alegria, 
Jackson et al. 2016). War time military and combat Veterans are a subpopulation that is particularly 
vulnerable to this illness as a result of high levels of sustained unpredictable stress and the 
increased probability for exposure to life threatening trauma. The estimated lifetime prevalence 
for PTSD among Veterans was 26.9% for women and 30.9% for men (Kang, Natelson et al. 2003). 
The lower frequency of PTSD diagnosed in women from this group, is attributed to women 
historically being barred from combat roles(Kilpatrick, Resnick et al. 2013) 
PTSD is diagnosed using 5 symptom categories dependent on duration of symptoms and 
the exclusion other diagnostic factors. Symptom categories are listed in the DSMV as follows: 
(Association 2013). 
A. Stressor(s) 
Exposure to actual or threatened death, serious injury, or sexual violence by:  
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● Directly experiencing  
● Witnessing as occurred to others  
● Learning that the traumatic event(s) occurred to a close family member or close 
friend  
● Experiencing repeated or extreme exposure to aversive details of the traumatic 
event(s) 
B. Intrusion Symptoms  
One (or more) of the following intrusion symptoms associated with the traumatic 
event(s):  
● Recurrent, involuntary, and intrusive distressing memories  
● Recurrent distressing dreams  
● Dissociative reactions (e.g., flashbacks)  
● Distress associated with traumatic event cues  
● Physiological reactions to internal or external cues  
C. Avoidance & Negative Symptoms   
Persistent avoidance of stimuli associated with the traumatic event(s) or negative 
alterations in cognitions and mood:  
● Avoidance of, or efforts to avoid, distressing memories, thoughts, or feelings 
● Avoidance of, or efforts to avoid, external reminders  
● Negative symptomology 
D. Cognitions & Mood  
Negative alterations in cognitions and mood that began or worsened after the 
traumatic event  
● Inability to recall key features of the traumatic event  
● Persistent negative beliefs about oneself or the world  
● Persistent distorted blame of self or others for causing the traumatic event or for 
     resulting consequences 
● Persistent negative trauma-related emotions  
● Markedly diminished interest in (pre-traumatic) significant activities  
● Feeling alienated from others (e.g. detachment or estrangement)  
● Constricted affect: persistent inability to experience positive emotions 
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E. Arousal & Reactivity  
              Marked alterations in arousal and reactivity associated with the traumatic 
event(s)  
● Irritable or aggressive behavior  
● Self-destructive or reckless behavior  
● Hypervigilance  
● Exaggerated startle response  
● Problems in concentration  
● Sleep disturbance  
F. Duration of the disturbance (Criteria B, C, D, and E) is more than 1 month.  
G. The disturbance causes clinically significant distress or impairment in social, 
occupational, or other important areas of functioning  
H. The disturbance is not attributable to the physiological effects of a substance (e.g., medication,   
                        alcohol) or another medical condition. 
 
Multiple studies have shown patients diagnosed with PTSD have markedly diminished 
quality of life, high rates of comorbid mental and physical health issues, as well as poorer treatment 
outcomes compared to the normal population (Kang, Natelson et al. 2003, Kessler, Chiu et al. 
2005, Senneseth, Alsaker et al. 2012). Moderate to severe PTSD symptoms can result in 
diminished social functioning/networks, difficulty maintaining employment, and deteriorating 
health combined with an increased risk of substance abuse, addiction and suicide. (Bremner, 
Southwick et al. 1996, Volpicelli, Balaraman et al. 1999, Kessler, Chiu et al. 2005, Jakupcak, 
Vannoy et al. 2010, Berenz and Coffey 2012, Meier, Lambert-Harris et al. 2014, Arnatt 2015, 
Patel, Elmaadawi et al. 2017). Researchers found an increased risk of suicide among Operations 
Iraqi Freedom and Enduring Freedom veterans of 25% among those who had been exposed to 
significant trauma (Kang and Bullman 2008). In addition, alarming statics report the tendency for 
patients to self-medicate with alcohol, marijuana, heroin, and benzodiazepines, in order to assuage 
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hyper arousal and anxiety-like symptoms (Patel, Elmaadawi et al. 2017). The risk for addiction 
gives physicians fewer treatment options for patients suffering from anxiety, injury and chronic 
pain, which in turn, exacerbates the patient’s PTSD symptoms (Brady, Killeen et al. 2000, Fareed, 
Eilender et al. 2013).  
Patients suffering from PTSD have high rates of comorbid anxiety, depressive, compulsive 
and addictive disorders. Many of the symptoms of PTSD overlap with other anxiety, compulsive, 
and depressive pathologies and thus give physicians options for pharmacological treatments 
without addictive properties. Unfortunately medications such as Selective Serotonin Reuptake 
Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs) have proven to be only 
moderately effective in an unpredictable subset of patients, despite the significant overlap of 
symptoms. (Jonas, Cusack et al. 2013, Flory and Yehuda 2015). To illustrate this point, 
comorbidity rates of a Major Depressive Episode (MDE) or Major Depressive Disorder (MDD) 
and PTSD are estimated to be as high as 48.5% and 42% (Kessler, Sonnega et al. 1995, Rojas, 
Bujarski et al. 2014).  
There are no known specific causes for why approximately 20% of those who experience 
a traumatic event eventually develop PTSD (Iribarren, Prolo et al. 2005). Intense study of the 
neural networks involved in stress regulation, adaptation to stress, and return to homeostasis after 
a traumatic event have revealed that PTSD is a syndrome driven by a multilayered dysregulation 
of both bottom up and top down emotional processing that results in an extreme pervasive 
reactivity to stress in the environment. One way to conceptualize symptom clusters in patients with 
PTSD is to consider the changes in the human brain affected by PTSD seem to mimic the cognitive 
and emotional patterns apparent when comparing top predators to vulnerable prey animals in the 
wild. These observations have led some clinicians to reconsider the postulation that PTSD is  
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neuronal dysfunction, and instead is a hyper adaptation that selects for hypervigilance focused on 
survival, over the very human drive for enrichments based on quality of life (Diamond and Zoladz 
2015, St-Cyr and McGowan 2018). Regardless of whether PTSD is a result of an evolutionary 
adaptation more profoundly expressed in some people over others, or is in fact a product of a 
pervasive degenerative disease processes in the brain, PTSD symptoms are not suited for modern 
human existence and cause the sufferer considerable difficulty in maintaining a reasonable 
standard of living. In addition these adaptations or disease processes do in fact contribute to 
considerable risk for other health problems and shortened life expectancy. Genetic risk factors, 
low socio economic status, early childhood trauma and high levels of neurosis are notable common 
risk factors in multiple symptom clusters resulting in diagnosis of anxiety, depressive, and 
compulsive disorders as well as PTSD (Hoffman and Mathew 2008, Rojas, Bujarski et al. 2014, 
Flory and Yehuda 2015). Due to the overlap in symptoms and risk factors, is not surprising that 
people diagnosed with PTSD are more often than not, also diagnosed with another co-occurring 
mental disorder. This has lead practitioners to consider using treatments effective for other mental 
disorders as first line treatments for PTSD. Providers have started characterizing patients with 
PTSD as belonging in sub categories based on comorbid disorders and symptoms (i.e. PTSD-
depressive type, dissociative type etc.) (Brown, Stout et al. 1998, Randall D. Marshall, Katherine 
L. Beebe et al. 2001, Lanius, Vermetten et al. 2010, Flory and Yehuda 2015). Besides the 
additional complexity that comorbid disorders add to the overall treatment prognosis and the 
probability of accurate diagnosis for patients with PTSD, treatments indicated for the additional 
diagnosis have less efficacy for a substantial percentage of PTSD patients. For instance, of the 
patients with MDD treated with SSRIs, approximately 40% reach full remittance of symptoms 
(Rush, Trivedi et al. 2006, Hoffman and Mathew 2008, Flory and Yehuda 2015) SSRI efficacy in 
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treating the same symptoms in patients also diagnosed with PTSD is as low as 20-30% (Brady, 
Pearlstein et al. 2000, Davidson, Rothbaum et al. 2001, Flory and Yehuda 2015). Combination 
therapies designed to target separate symptom clusters are often time consuming, expensive and 
greatly increase the probability of patient non-compliance due to side effects.  
Exposure Therapy is a behavioral intervention for PTSD that has been moderately effective 
at reducing fear related anxiety, dissociative and depressive symptoms of PTSD by employing 
techniques to stimulate post-trauma fear extinction learning. PTSD symptoms, including traumatic 
reexperiencing the event in a dissociative state (flashbacks), hyperarousal, and negative changes 
in beliefs and feelings, are some of the most disruptive aspects of PTSD affecting a person’s 
productivity and quality of life. Exposure therapy relies on exposing an individual to aspects of 
the original trauma without the consequences (pain, injury, physical discomfort, separation from 
resources, etc.) or context of the original stressor. Studies have shown significant improvements 
in these symptom clusters over other psychological treatments in approximately 50% of patients, 
however the effect sizes of clinically significant change were small (h2 =0.16/0.24) (Taylor, 
Thordarson et al. 2003). For reviews of the efficacies and treatment outcomes involving 
pharmacological and psychological treatment options for PTSD see (Hoffman and Mathew 2008, 
Steckler and Risbrough 2012, Jonas, Cusack et al. 2013).  
Along with the significant suffering PTSD patients endure, there are important societal and 
economic burdens associated with this illness. The overall cost born by society for all anxiety type 
disorders is 42.3 billion dollars annually. This figure includes: indirect work place costs, 
psychiatric and non-psychiatric medical care, prescription drugs and mortality costs (Kessler, 
Berglund et al. 2005, Alegria, Jackson et al. 2016). Patients with PTSD have one of the highest 
rates of medical service utilization within this category, and it is estimated that 50% of all 
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outpatient therapy clients are suffering from PTSD (Kessler, Sonnega et al. 1995, Kessler, Chiu et 
al. 2005). Costs estimated by the Veterans Administration to treat PTSD patients for 2 years, post 
military deployment, ranges between $5904- $25,757 per patient (Terra C. Holdeman 2009). 
Given the long term health consequences and enduring symptomology of PTSD, the overall cost 
of treating thousands of veterans is enormous. in addition, PTSD is the fastest growing disability 
benefit payout category within the United States government’s 49 billion dollar annual veteran’s 
disability budget.   
 There is abundant preclinical and clinical data to indicate that research concerning 
abnormalities in fear learning and subsequent fear extinction is essential to understanding and 
treating PTSD. Pharmacological treatments and psychological interventions like Exposure 
Therapy is limited and the complete reversal of PTSD symptoms is uncommon. Understanding the 
molecular and circuit level mechanisms that prevent successful fear extinction and normalization 
of the stress response after a traumatic event, may lead to a targeted pharmaceutical solution that 
garners better treatment outcomes with fewer side effects. However, given the lack of 
comprehensive treatments available, the clear multilayered neural complexity of the disease, and 
significant societal burden associated with PTSD, research to discover how PTSD develops in 
hopes to discover an intervention to halt the progression of the disorder in early stages after trauma, 
is an important step towards lowering the net cost and suffering associated with this disorder. The 
focus of the following research is to investigate the complex molecular pathways associated with 
retention of fear learning following acute stress in rodents as a model for the development of 
PTSD. 
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The Hypothalamic-Pituitary-Adrenal Axis and the Stress Response in PTSD 
The normal stress response is an adaptive, protective reaction to perceived danger or 
heightened stimulation from the organism’s physical or emotional environment. The activation of 
the autonomic nervous system and hypothalamic-pituitary-adrenal axis (HPA axis) occurs in 
response to potential risk. It redirects the organism’s physiological resources from homeostasis to 
physically prepare the body to illicit a reaction ideally suited towards survival of the organism 
(fight or flight response) (McEwen 2007). In response to stress, the brain secretes several 
neuropeptides through a complex neural network that converge on the hypothalamic 
paraventricular nucleus and results in activation of the HPA axis (Fig. 1.1).     
Activation of the HPA axis initiates a cascade of hormone and hormone releasing factors to 
be released. This cascade regulates specific autonomic sequences effecting important survival 
mechanisms including blood glucose levels, energy metabolism, blood pressure, cognition and 
arousal, and the immune system (McEwen 2007). In addition, adrenal corticosteroid hormones bind 
to two types of nuclear receptors [glucocorticoid receptors (GR) and 
mineralocorticoid receptors (MR)] that act as transcriptional regulators that target a variety of genes 
involved in cognition and emotion regulation. The HPA axis through release of glucocorticoids, 
functions as a “master switch” providing jurisdiction over neuronal and network responses that 
underlie behavioral adaptation (de Kloet, Joels et al. 2005). For a more in depth overview of specific 
regulation of these pathways see (de Kloet, Joels et al. 2005, Smith and Vale 2006).  
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Figure 1.1. Activation of the HPA axis A) Sensory information regarding stressor is 
processed through the corticolimbic system and relays information to the hypothalamic 
paraventricular nucleolus (PVN). B) CRH travels through the hypophyseal portal system 
to the anterior pituitary to stimulate secretion of adrenocorticotropic hormone (ACTH).  
C) ACTH is carried through the blood stream to adrenal cortex and triggers the synthesis 
and  release of Glucocorticoids (cortisol). D) Cortisol circulates through the body and 
activates the autonomic sympathetic nervous system responsible for production and 
release of Catecholamines (Epinephrine (Norepinephrine, and Aldosterone) that control 
the flight or fight response. E) Increases of cortisol inhibit further release of CRH and 
ACTH from the hypothalamus and pituitary in order to allow the organism to return to 
homeostasis once the threat is resolved.  
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While activation of the stress response is adaptive and protective in the short term, over 
stimulation and prolonged exposure to stress inducing conditions has deleterious effects on an 
organism’s physical and emotional well-being. Allostatic Overload is a term used to describe the 
physiological consequences of sustained hyper activation of the HPA axis (McEwen and Stellar 
1993). Over time and with repeated challenges to normal physiological adaptations required for 
optimal and efficient survival of the organism, the processes involved in allostasis “achieving 
stability through change” are overwhelmed. This hyperactivity results in a failure to return to and 
maintain homeostasis through disruptions in HPA negative feedback functioning that contributes 
to dysregulation of important mechanisms required for proper immune function, energy 
expenditure, cognition and appropriate scaling during threat assessment. (McEwen 1998, McEwen 
and Seeman 1999, Smith and Vale 2006, McEwen 2007). Over exposure to stress can lead to 
allostatic modifications in one system that results in hyper activation of another (McEwen 1998). 
For example, chronic elevation of cortisol is a risk factor for metabolic diseases such as diabetes 
and obesity, cardiovascular disease, anxiety disorders, addiction, cancer and can result in a 
significantly shorter life span (Schnall, Landsbergis et al. 1994, Whitworth, Williamson et al. 2005, 
Sinha 2008, Hackett, Kivimaki et al. 2016, Daimon, Kamba et al. 2017, Papale, Seltzer et al. 2018).  
Cortisol levels are used as a barometer to measure HPA axis activity at basal levels 
throughout the day, and in response to stress. Temporal levels of cortisol are regulated by the 
suprachiasmatic nucleus and hypothalamus in response to circadian rhythm signaling that regulates 
cortisol levels to support arousal during the sleep wake cycle (Weitzman, Czeisler et al. 1981). 
Other factors causing fluctuations in cortisol are from external cues that can influence this pattern 
as a residual consequence of HPA hyper activity in response to stress, or lower activity due to 
relaxing circumstances that can carry over into the following day. It is well established that the 
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circadian cortisol pattern in people with psychological disturbances is altered, causing changes in 
a variety of activities in daily living (Stetler, Dickerson et al. 2004).  
Specific dysregulation of the HPA axis in patients with PTSD has been difficult to define. 
Surprisingly, patients suffering from PTSD have been reported to have decreased basal levels of 
cortisol, enhanced HPA feedback function and progressive sensitization of the HPA axis overall 
(Yehuda and Seckl 2011). However, there has been some conflicting data regarding cortisol levels 
in patients with PTSD and this issue has not been completely resolved (Yehuda, Southwick et al. 
1990, Yehuda 2002, Meewisse, Reitsma et al. 2007, Yehuda and Seckl 2011, Morris, Compas et 
al. 2012, Tajima-Pozo, Montes-Montero et al. 2013). It does appear that cortisol levels can be 
expressed differently depending on comorbid factors, gender, and the type of trauma experienced. 
The most well studied comorbid diagnosis concerning this issue is MDD (Kendall-Tackett 2000, 
Meewisse, Reitsma et al. 2007, Morris, Compas et al. 2012).  
Patients with a diagnosis of MDD show increased levels of basal cortisol, impaired HPA 
feedback function and progressive desensitization of the HPA axis (Kendall-Tackett 2000). Given 
opposing cortisol levels were reported for MDD and PTSD, it stands to reason that patients with 
comorbid disorders will present with yet another pattern of HPA dysfunction. A meta-analysis of 
HPA feedback function involving 47 independent studies compared levels of cortisol in patient 
diagnosed with PTSD, PTSD and MDD, trauma exposed participants (TE) (that did not meet 
criteria for PTSD or MDD), and normal controls. Patients diagnosed with PTSD had lower basal 
cortisol levels in the am, pm, and “daily output cortisol levels” than normal controls. TE 
participants revealed lower levels of pm cortisol but no significant changes in other measures 
compared to the normal controls. In the final comparison of cortisol output PTSD+MDD 
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participants had lower am cortisol levels, higher pm, and lower daily output cortisol levels than 
normal controls (Morris, Compas et al. 2012). 
 Morris et. al next analyzed studies measuring the HPA feedback function that utilized the 
dexamethasone suppression test (DST). The DST measures the production of cortisol following 
administration of a synthetic glucocorticoid that inhibits cortisol production in the HPA axis. 
Measuring “post DST” cortisol levels after exposure to a controlled stressor indicates the 
efficiency of HPA negative feedback inhibition (Tajima-Pozo, Montes-Montero et al. 2013). 
Lower levels of cortisol measurements after stress exposure indicates a stronger HPA negative 
feedback inhibition. Enhanced negative feedback inhibition on the hypothalamus and anterior 
pituitary within the HPA axis will result in decreased levels of CRH and ACTH secretion and 
diminished cortisol output (Yehuda and Seckl 2011, Yoshida, Uchigashima et al. 2011). While it 
may seem counter intuitive that patients with PTSD have lower levels of the major hormone related 
to stress, chronic decreases in levels of cortisol results in changes in glucocorticoid receptor (GR) 
surface expression and sensitivity to fluctuations in cortisol (de Kloet, Joels et al. 2005, Gola, 
Engler et al. 2014). Evidence suggests that patients with PTSD have a lower threshold required for 
activation of the HPA axis and may explain why symptoms of PTSD manifest as a sensitivity to 
sudden noises, exaggerated startle response, lower tolerance for noxious stimuli.  
Meta-analysis of the data revealed that PTSD, PTSD+MDD, and TE participants exhibited 
enhanced HPA negative feedback inhibition compared to normal controls. This analysis supports 
the hypothesis that exposure to trauma causes hyperactivation of the HPA axis and negative 
feedback inhibition. The authors of this study caution that it is still uncertain as to whether having 
enhanced negative HPA feedback inhibition is a risk factor for developing PTSD or if PTSD causes 
a change in the regulation of this process given there was no significant difference in “post DST” 
 13 
cortisol levels between TE and PTSD participants (Morris, Compas et al. 2012). A cohesive 
explanation for how trauma results in the pervasive symptoms found in PTSD requires an extended 
examination of the cortico-limbic system upstream of the HPA axis. Understanding cortico-limbic 
signaling that results in triggering or suppressing stress responses may lead to novel approaches 
for reducing or preventing dysfunction precipitated by stress exposure.  
 
 Cortico-limbic Regulation of Stress, Fear Learning, and Fear Extinction  
The diagnostic features specific to PTSD are hypothesized to be a failure of higher order 
brain regions in the cortico-limbic system to dampen exaggerated symptoms of arousal and distress 
mitigated through the brain’s main threat detection nucleus known as the amygdala. Brain regions 
that have been found be functionally disrupted in persons suffering from PTSD have in common 
that they are all involved in some aspect of visuospatial processing, fear learning, fear retention 
and memory. The following section gives a brief overview of the key brain structures within this 
system and differences in function related to PTSD pathology (Fig. 1.2). 
 Specific characteristics of distinct stressors determine the degree and extent of HPA axis 
stress responses. Stressor type and intensity illicit different responses from specific brain regions 
that converge onto the PVN via precisely regulated pathways that vary based not only on the type 
of stress, but also on the individual’s experience, gender, and age. Limbic structures synthesize 
sensory information from sensory cortices and combined with cue information regarding the 
potential threat, assign emotional valence to the stimuli for an optimized response. The limbic 
system is comprised of multiple sub-nuclei and cortices with multiple layers of inhibitory and 
excitatory efferent and afferent connections between them. The limbic system is often referred to 
as the “feeling and reacting” center of the brain. Psychological stress elicited during Pavlovian fear   
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conditioning and fear extinction will be the primary focus of this review of the literature 
concerning corticolimbic regulations of the stress response.  
Fear conditioning and fear extinction learning is a model for processes involved in normal 
adaption after exposure to acute stress. Multiple studies in humans and rodent show similarities in 
brain activity during tasks involved in fear learning and fear extinction. Given these similarities 
and the inability to study human molecular pathways in depth, the fear conditioning and fear 
Figure 1.2. Summary of key brain regions in the cortico-limbic regions involved in 
regulating HPA axis. Many of the brain regions involved in fear conditioning and fear 
extinction that are known to directly or indirectly regulate the HPA axis. The structures 
included in this figure are also regions that have been correlated with significant 
disruptions related to PTSD symptoms and  pathophysiology.  
 
 15 
extinction paradigm is a useful model for exploration of the molecular pathways involving 
regulation of fear learning and normalization of fear behavior after trauma that prevents 
development of maladaptive generalized anxiety to other contexts. Fear conditioning and fear 
extinction paradigms are models used to mimic fear learning and extinction in the environment. 
Fear learning as well as extinction of that fear is important for survival. Animals must learn to both 
recognize and respond to threats, as well adapt that learning to specific contexts to facilitate the 
mouse’s ability to return to foraging for food and activities of daily life also required for survival. 
PTSD is thought to be a failure of the fear extinction learning paradigm mediated by a complex 
neural and molecular system of layered fear processing and learning. Figure 1.3 shows a schematic 
drawing of a stereotypical fear conditioning and fear extinction paradigm used in research and is 
the model utilized in the study described in Chapter II. Figure 1.3 shows a schematic drawing of a 
stereotypical fear conditioning and fear extinction paradigm and is the model utilized in the study 
described in Chapter II. 
Fear extinction is dependent on inhibition of fear responses learned during fear 
conditioning. Both human and rodents will respond to a conditioned stimuli at pre-conditioned 
levels if fear extinction is sufficiently learned. However, even after a conditioned response has 
been neutralized with fear extinction training, over time if the organism is returned to the original 
context experienced during conditioning, or is subsequently experiences another trauma, the 
conditioned fear response will reappear. (Pavlov 1927, Rescorla and Heth 1975, Bouton and Bolles 
1979). This behavioral observation led to the hypothesis that during fear extinction a conditioned 
fear memory is not over written or “forgotten” but rather a new learning results in a memory 
capable of inhibiting the conditioned response.   
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A substantial amount of research has been dedicated to describing and searching for the 
underlying mechanisms involved in fear learning and fear extinction memories with hopes that 
revealing normal fear responses will shed light on maladaptive adaptations, by comparison. For 
reviews on this topic see, (Myers and Davis 2007, Quirk and Mueller 2008, Herry, Ferraguti et al. 
Figure 1.3. Fear conditioning paradigm. Fear conditioning requires a learning to pair a 
neutral stimuli conditioned stimuli (CS) with an adverse event unconditioned stimuli 
(US). In the paradigm depicted above mice are placed in a chamber with a metal grid 
capable of delivering a shock (US) at the end of a 30 second auditory cue (CS). After a 
series of several tone/shock pairings the mouse will start to anticipate a shock when it 
hears the tone and freeze as an autonomic response to acute stress and fear. 24 hours after 
this training session the mouse will return to the chamber, however the walls and flooring 
will be fitted with inserts to change the visual and tactical cues from the preceding training 
days. Vanilla scent will be added under the floor insert to remove any learned olfactory 
association the mouse may have learned during the training day. Consecutive 30 second 
tones will play without the shock 20 times for 2 consecutive days. As the mouse learns that 
in this chamber context the tone will not accompany a shock the freezing behavior will 
subside. On the final day in this paradigm mice will remain in the chamber for longer 
baseline measurement (no tones) to establish residual generalized fear and a final test of 
freezing behavior post fear extinction learning. 
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2010, Pape and Pare 2010, Radulovic and Tronson 2010). The hypothalamus, hippocampus, 
prefrontal cortex, and amygdala have emerged as the principal brain regions involved in fear 
conditioning, fear learning and the stress response. Examples of their roles in these processes are 
summarized in the remainder of this section.  
The hypothalamus is the primary output center for the limbic system. This structure is made 
up of multiple sub nuclei that regulate temperature, hunger, sexual desire, and monitor internal 
signals related to homeostasis such as blood glucose, sodium levels, and osmolarity. It receives 
inputs from most of the body, as well as receives information directly from retina and olfactory 
bulb. Hypothalamic output functions to regulate endocrine responses, the autonomic nervous 
system and multiple complex behaviors related to appetitive and adaptive functioning. As 
discussed earlier, the hypothalamus contains the paraventricular nucleus, which functions to 
initiate the HPA axis signaling cascade in response to a perceived threat or stress. Multiple studies 
have revealed significant sensitivity to cortisol fluctuations within the hypothalamus. The 
paraventricular nucleus has one of the  highest levels of GR expression in the brain. GR expression 
is also high in the hippocampus and other limbic neurons projecting to the GABA (γ-aminobutyric 
acid) inhibitory network surrounding the PVN (peri-PVN region) which functions primarily to 
inhibit the HPA axis and regulate HPA inhibitory tone (Herman 1993). GR distributions in both 
structures are significantly changed in PTSD pathology to favor HPA axis hypersensitivity (de 
Kloet, Joels et al. 2005). Tonic disruptions of endocannabinoid signaling, which further 
regulates HPA axis sensitivity, is also implicated in PTSD and will be discussed in further detail 
later in this section (Cota 2008).  
The hippocampus and medial prefrontal cortex (mPFC) primarily serve to exert an 
inhibitory action on the HPA axis. This top-down control over the HPA axis is weakened as a 
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result of PTSD. The hippocampus synapses onto the hypothalamus through the fornix and is an 
important inhibitory mediator of HPA signaling. In the context of fear conditioning the 
hippocampus has been shown to contribute more to contextual fear memory than that elicited from 
an auditory cue. When the hippocampus was lesioned 24 hours after fear conditioning, rats 
exhibited fear retention to an auditory cue but context specific fear retention was abolished (Maren, 
Aharonov et al. 1997). However, when specific regions of the ventral hippocampus were lesioned 
in rodents, it resulted in a marked decrease in freezing behavior in response to both a contextual 
and auditory conditioned stimulus and contextual stimuli (Maren 1999). There is still some debate 
on the specific role the hippocampus may play in generation and retention of fear learning and 
retention (Kim and Jung 2006).  
During fear extinction the hippocampus regulates important aspects of context-dependent 
fear expression and fear extinction. Data acquired through fMRI imaging of the human brain 
reveals that hippocampal activation to the conditioned stimulus occurs in the extinction context 
but not in the conditioning context, implying that hippocampal dysfunction may be a contributing 
factor to generalized fear responses independent of the original context of an acquired fear 
(Kalisch, Korenfeld et al. 2006). In addition hippocampal activity was correlated with activity in 
the mPFC. Hippocampal and mPFC interactions may be important for regulation of how the 
context in which the stressor is experienced effects fear extinction learning (Kalisch, Korenfeld et 
al. 2006).   
Studies involving patients with PTSD have revealed a significant reduction in hippocampal 
volume. This reduction has been hypothesized to be a result of neurotoxic effects of repeated 
exposure to stress and glucocorticoids (Sapolsky, Krey et al. 1985, Gilbertson, Shenton et al. 2002, 
Shin, Rauch et al. 2006, Conrad 2008). Some doubt that this volume decrease is a result of PTSD 
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and suggest it may be a contributing factor in developing the disorder, based on twin studies 
showing that the twin not exposed to trauma also had a smaller hippocampal volume (Gilbertson, 
Shenton et al. 2002, Pitman, Sanders et al. 2002, Shin, Rauch et al. 2006). Hippocampal deficits 
may decrease the ability to adequately distinguish between safe and unsafe environments and 
increase the likelihood of HPA axis hyperactivity and impaired fear extinction (Sherin and 
Nemeroff 2011). It is also possible that PTSD symptoms related to memory and hippocampal 
function develop as a result of the disorder and not have a specific role in contributing to the 
development of the disease. Various nuclei located in the prefrontal cortex and analogous 
structures in rodent models have been implicated in the regulation of the HPA axis and contribute 
to both diminished function in PTSD and fear learning/extinction paradigms. 
 Important inhibitory control over the stress response and emotional regulation is mediated 
by through the mPFC both directly and through indirect connections with the amygdala and 
hippocampus. The mPFC also regulates important aspects of the extinction of conditioned fear by 
inhibiting learned fear responses (Shin, Rauch et al. 2006). In addition experiments with rodents 
show that lesions in the mPFC render the animal incapable of fear extinction following a fear 
conditioning paradigm (Morgan, Romanski et al. 1993). Neuroimaging data reveal that patients 
with PTSD have decreased activation of mPFC in response to a variety of stress inducing stimuli 
(Bremner, Narayan et al. 1999, Lanius, Williamson et al. 2003, Bremner, Vermetten et al. 2004, 
Britton, Phan et al. 2005). Studies involving patients with PTSD have revealed decreased function 
and volumes within specific regions in the frontal cortex most notably within the Anterior 
Cingulate Cortex (ACC). Reductions in ACC volume are inversely proportional to the severity of 
PTSD symptoms reported in patients (Woodward, Kaloupek et al. 2006). The ACC has been 
shown to regulate executive control over selection and prioritization of stimuli and selective 
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attention. In PTSD pathology, ACC dysfunction results a failure to filter stressful stimuli and 
adequately drive appropriate distinction between the stimulus and conditioned fear associations 
resulting from the original trauma (Bench, Frith et al. 1993). In contrast to the studies related to 
hippocampal volume, the decreased volume of frontal cortex seems to be as a result of PTSD and 
not a predisposing risk factor for developing the disorder (Kasai, Yamasue et al. 2008).  
The infralimbic cortex (IL) plays an important role in inhibiting conditioned fear responses 
following extinction learning. In an auditory cue-fear conditioning paradigm, lesioning the IL in 
rats resulted in animals that exhibited normal within session fear extinction, however 24 hours 
later, the rats had spontaneous recovery of 87% of freezing behavior on cue compared to 27% of 
non-lesioned controls. Rats with lesions of the mPFC that did not include the IL showed no 
impairment of fear extinction learning or recall of that learning on the following day. The authors 
interpret these findings that IL signaling is not required for fear extinction learning but is required 
for recall of extinction after a 24 hour delay (Quirk, Russo et al. 2000). Projections from the IL 
synapse directly onto the GABAergic cells in the lateral subdivision of the central nucleus (CeL) 
and intercalated (ITC) cell masses of the amygdala and are thought exert inhibition of CeL output 
(Cassell and Wright 1986). Micro-stimulation of the IL paired with conditioned tones in rats 
reduced freezing behavior in response to the tone, and markers of neuronal excitability were 
detected in the IL during extinction recall (Cassell and Wright 1986, Quirk, Russo et al. 2000, 
Herry and Garcia 2002).  One interesting study found that “brief uncontrollable stress” resulted in 
dendritic retraction in IL neurons, which the authors hypothesized facilitated resistance to fear 
extinction during acute trauma (Izquierdo, Wellman et al. 2006). This data supports the hypothesis 
that the IL serves to inhibit amygdala activity to facilitate behavioral expression of fear extinction 
learning.  
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Anatomical studies and electrophysiology data show that regulation of the HPA axis by 
the hippocampus and prefrontal cortex projections are indirect and converge on secondary 
structures such as the bed nucleus of the stria terminalis (BNST) that in turn regulate CRH release 
from the PVN.  Additionally there is complex circuitry between these structures implicated in 
PTSD pathology. For a review of these circuits see (Herman, Ostrander et al. 2005, Choi, Furay et 
al. 2007, Jin and Maren 2015). 
In contrast to the hippocampus and mPFC’s indirect inhibitory drive on the HPA axis, the 
amygdala supports activation via direct and indirect connections to the hypothalamus (Feldman, 
Conforti et al. 1995). The amygdala is the structure in the brain responsible for emotional 
processing, and is critical for associative fear learning and the acquisition of fear responses. The 
amygdala is the most strongly associated structure with the pathophysiology of PTSD and 
hyperactivity within the HPA axis. Acute stimulation of the amygdala in rodents results in 
increased synthesis and release of glucocorticoids (Matheson, Branch et al. 1971, Gray, Carney et 
al. 1989, Feldman, Conforti et al. 1995, Van de Kar and Blair 1999). Activation of the HPA axis in 
response to noxious fumes and restraint stress was diminished after bilateral amygdala lesions 
(Feldman, Conforti et al. 1995). In human studies,  amygdala hyperactivity in response to negative 
stimuli has been consistently measured by fMRI in patients presenting with PTSD (Yehuda and 
Seckl 2011). Patients with amygdala lesions fail to respond to threat predictive cues and although 
the interpretation must be guarded, deep brain stimulation which inhibited the basolateral 
amygdala (BLA) resulted in dramatic relief of severe PTSD symptoms in one patient (LaBar, 
Gatenby et al. 1998, Funayama, Grillon et al. 2001, Whalen, Kagan et al. 2005, Langevin, Koek 
et al. 2016).  
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Given the extensive study of the rodent amygdala and associated fear neurobiology, 
circuitry involving amygdala’s 13 sub nuclei are relatively well understood. Complex intra-
amygdala circuits regulate fear conditioning via glutamatergic inputs from the sensory cortices and 
the thalamus (Fig 1.4).  Not surprisingly, most of the studies involving regulation of fear 
conditioning and fear extinction learning involving amygdala circuitry have been done with rodent 
models. Human studies using fMRI have at least confirmed that there are increases in activity in 
the amygdala during a simple fear conditioning task and that amygdala activity is reduced in 
parallel to fear extinction learning.  The rodent amygdala nuclei can be categorized into roughly 
into the 3 major sections with specific roles in acquisition of fear and fear expression during fear 
conditioning, and fear extinction. The basolateral complex (BLA) is the input center of the 
amygdala and is subdivided further into the basal nucleus (BA) and the lateral nuclei (LA). 
Intercalated cells (ITC) are three distinct masses of inhibitory cells including: dorsal (ITCd), 
ventral (ITCV), and lateral (ITCl). The central nucleus (CeA) is major output center of the 
amygdala and is divided into the centromedial (CEm) and centrolateral (CEl) nuclei (Maren 2001). 
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The BLA is the main “sensory interface” of the amygdala. Lesions in the BLA produce 
deficits in the animal’s Pavlovian fear response and expression (LeDoux, Cicchetti et al. 1990, 
Campeau and Davis 1995, Cousens and Otto 1998). Specifically the BA seems to be important for 
fear conditioning as the LA is associated with the behavioral response to learned fear (Amorapanth, 
LeDoux et al. 2000).  
 The CeA functions as the direct and indirect output nuclei for fear response systems. Direct 
stimulation of the CeA will cause the organism to respond in the same innate conditioned fear 
Figure 1.4.  Representative amygdala circuitry involved in fear conditioning (a) and (b) 
extinction. Solid lines indicate neural connections strengthened during the acquisition of 
fear or extinction learning. Dotted lines indicate pathways that are less active or partially 
inhibited within these paradigms. Red lines indicate glutamatergic projections, Blue lines 
indicate GABAergic projections. A) During fear conditioning excitatory inputs from 
cortical sensory, sensory association areas, and the thalamus disinhibit LA glutamatergic 
neurons projecting into the BA. Excitatory synapses within the BA excite inhibitory neurons 
involved in inhibition of extinction specific populations of neurons and also and directly 
stimulate CEm MSNs with net result of increased output from the CeA. B) During fear 
extinction excitatory inputs from cortical sensory, sensory association areas, and the 
thalamus stimulate inhibitory neurons and dampen signals to fear neurons in the BA.  
Projections from the infralimbic areas excite extinction specific microcircuits within the BA 
as well as ITCv MSNs that serve to increase the inhibitory drive on CeA pathways. The net 
result of these circuits is decreased output from the CeA to the hypothalamus and brainstem 
(flight or fight response). This figure is based on and modified after (Lee, Kim et al. 2013). 
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behavior independent of conditioning or conditioned stimuli (Iwata, Chida et al. 1987). Lesions of 
the CeA cause disruptions in fear acquisition and fear conditioning (Hitchcock and Davis 1986, 
Iwata, Chida et al. 1987, Kim and Davis 1993, Young and Leaton 1996). Studies that lesioned 
brain regions receiving inputs from the CeA show deficits in fear responses particular to that 
region’s function which indicates the CeA is the “final common pathway for the generation of 
learned fear responses” (LeDoux, Cicchetti et al. 1990, De Oca, DeCola et al. 1998, Amorapanth, 
LeDoux et al. 2000, Maren 2001).  The CeA is not simply an outward relay station, it also plays a 
role in fear conditioning and fear extinction through CeA microcircuits. Within the CeA, the CEm 
plays a role in fear expression, and the CEl is important for fear learning. Furthermore discrete 
“CElon” and “CEloff” neurons are capable of a biphasic inhibition of CEm projections to the brain 
stem in response to a conditioned stimulus. CEloff neurons disinhibit CEm output neurons and 
facilitate behavioral expression of fear conditioning. Fear conditioning increases the proportion of 
CEloff cells and fear extinction increases the proportion of CElon cells that regulate CEm output 
(Duvarci, Popa et al. 2011).  
The ITC are distinct clusters of GABAergic neurons interspersed between the BLA and 
CeA and are thought to mediate signals between these two amygdala sub regions (Nitecka and 
Ben-Ari 1987, McDonald and Augustine 1993). The BLA synapses onto the ITCs which then 
project to the CeA (Royer, Martina et al. 1999). Interestingly, systematic microsimulation of these 
clusters revealed a spatiotemporal inhibition pattern that indicates that ITCs function as a complex 
feedforward inhibition within the amygdala to regulate the flow of information between the 
receiving and output nuclei. This distinct amygdalar neural network results in computational 
capabilities within the amygdala, wherein CeA output is not just dependent on the type and 
intensity of sensory input to the BLA, but can be further distinguished based on input timing and 
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spatial properties from cell populations within the BLA (Royer, Martina et al. 1999). Other brain 
regions besides the amygdala are known to synapse directly onto the ITC.  The infralimbic area of 
the mPFC has glutamatergic synapses on ITCs and are thought to increase inhibitory drive on the 
CeA during fear extinction (Likhtik, Popa et al. 2008).   
The cortico-limbic circuitry involved in regulating activation of the HPA axis, and fear 
conditioning/fear extinction is clearly a tightly regulated network reliant on highly plastic synaptic 
connections regulated by multiple layers of neurotransmitter release, receptor expression, and 
tightly controlled protein-protein interactions within distinct synapse specific microdomains. The 
endocannabinoid system has immerged in the past decade as extremely important for the regulation 
of homeostasis, protection from neurotoxic effects of stress, and short term plasticity required for 
adaptation to a stress laden environment. The remaining section will cover the molecular 
regulation and expression of eCB signaling with a particular emphasis on what is known regarding 
eCBs during acute stress, fear learning and extinction.  
 
The Endogenous Cannabinoid System 
The endogenous cannabinoid (eCB) system is a retrograde signaling pathway that uniquely 
allows for the post-synaptic neuron to regulate neuro transmitter release by the pre-synaptic 
neuron. Generally this mechanism is employed in response to high levels of activity and is 
protective against excitotoxicity as well as being important for transient regulation of neuronal 
circuits involved in multiple physiological circumstances. The study of eCBs was initially 
motivated by the search for the underlying mechanism responsible for the effects of the Cannabis 
sativa plant and its primary psychoactive component, Δ9 -tetrahydrocannabinol (THC) (Gaoni and 
Mechoulam 1971). Cannabinoid Receptor 1 (CB1R) and Cannabinoid Receptor 2 (CB2R) are the 
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two cannabinoid receptors that were discovered and have only been understood to be important 
neuromodulators within the past two decades.  CB1R is mainly expressed in the  central nervous 
system (CNS) with the CB2 subtype preferentially expressed in the periphery(Matsuda, Lolait et 
al. 1990, Munro, Thomas et al. 1993, Glass and Felder 1997). The two eCB endogenous ligands 
arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG)  are expressed 
ubiquitously throughout the brain (Devane, Hanus et al. 1992, Sugiura, Kondo et al. 1995). There 
are other possible lipid binding partners for CB1R and CB2R, however none have been shown to 
be physiologically relevant in the mammalian brain thus far  (Huang, Lo et al. 2001). 
The CB1R is a transmembrane G-protein coupled receptor (GPCR) which predominantly 
couples to Gαi/o expressed in presynaptic axon terminals. CB1R is evolutionarily conserved across 
species and is approximately 97% homologous between rodents and humans (Chakrabarti, Onaivi 
et al. 1995). A brief over view of the eCB pathway including important enzymes regulating the 
most abundant eCB (2-AG) synthesis and hydrolysis can be found in figure 1.5 (Pertwee 1997, 
Kano, Ohno-Shosaku et al. 2009).  
There is still a frustrating lack of evidence regarding how eCBs traffic from the post 
synaptic to the presynaptic neuron. There is an ongoing debate concerning whether there is active 
transportation of eCBs via a pump/carrier molecule or passive diffusion. The CB1R ligand binding 
pockets are located within the transmembrane helices which is consistent with the indication that 
eCBs do in fact diffuse through the membrane at some point in their journey to the presynaptic 
target (Song and Bonner 1996, Beltramo, Stella et al. 1997). However, eCB signaling has such 
tight control over synaptic function in perisynaptic microdomains that it seems unlikely to be left 
to passive diffusion alone.   
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Figure 1.5 Endocannabinoid retrograde signaling dampens presynaptic release of 
neurotransmitter via a postsynaptic molecular cascade resulting in decreased calcium 
signaling in presynaptic neuron. (a) Endocannabinoids are synthesized in the 
postsynaptic cell in response to increased concentrations of calcium levels after 
presynaptic release of neurotransmitter and binds postsynaptic Ca2+ permeable ion 
channels and/or activate G-protein coupled protein receptors (GPCRs) (a). Neuronal 2-
AG is synthesized on demand in the postsynaptic membrane via cleavage of DAG by 
diacylglycerol lipase α (DAGLα) (b), then is trafficked to the presynaptic cell via 
mechanism that is still not well understood (c). 2-AG then binds and activates the CB1R 
(d). Activation of the CB1R (inhibitory GPCR) results in a decrease of calcium influx into 
the presynaptic cell and subsequently reduces the amount of neurotransmitter release 
from the presynaptic neuron. Finally, 2-AG is degraded by MAGL in the presynaptic cell. 
(e) This pathway in effect enables the postsynaptic cell to dampen presynaptic signaling 
inducing a short term depression of the neuronal circuit.  
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By in large, CB1Rs are localized to the perisynaptic membrane on the presynaptic terminal 
in many highly plastic limbic brain regions relevant for fear conditioning, emotional processing 
and fear extinction learning  (Kawamura, Fukaya et al. 2006, Yoshida, Uchigashima et al. 2011, 
Ramikie, Nyilas et al. 2014). Indeed, eCB signaling is highly involved in the regulation of 
important neural circuitry that regulates downstream activation of the HPA axis and autonomic 
nervous system(Wamsteeker, Kuzmiski et al. 2010, Gray, Vecchiarelli et al. 2015) (Morena, Patel 
et al. 2016). AEA is the less abundant of the two eCBs and acts as only a partial agonist at the 
CB1R. There are several pathways for AEA synthesis and it is still unclear which pathway is 
preferential in specific circumstances (Astarita and Piomelli 2009) (Simon and Cravatt 2008, 
Ueda, Suzukamo et al. 2013). Fatty acid amide hydrolase (FAAH) is the primary enzyme that 
terminates AEA signaling by hydrolysis (Cravatt, Giang et al. 1996). 
 2-AG is the most abundant eCB in the CNS. 2-AG has been found to be important for 
return to homeostasis after acute stress. It was originally thought to be simply an intermediate in a 
mechanism to convert diacylglycerols into free arachidonic acid (AA) (Prescott and Majerus 
1983). 2-AG is synthesized ‘on demand’ in response to postsynaptic depolarization and Ca2+ 
influx, activation of Gq/11 coupled GPCRs, and in greater amounts in response to synchronized 
Ca2+ influx and Gq/11 8 activity (Kreitzer and Regehr 2001),(Kano, Ohno-Shosaku et al. 2009, 
Ohno-Shosaku and Kano 2014, Ramikie, Nyilas et al. 2014) (Hashimotodani, Ohno-Shosaku et al. 
2013). Multiple pathways can result in 2-AG signaling, however it is generally accepted that 2-
AG is synthesized by DAGLα in response to GPCR activity is the predominate pathway utilized 
in the CNS. DAGLα activity is required for 2-AG facilitated retrograde synaptic inhibition, its 
primary function in the CNS (Stella, Schweitzer et al. 1997, Bisogno, Howell et al. 2003) The 
precursor for 2-AG is the DAG, 1-stearoyl-2-arachidonoyl-snglycerol (SAG), which is produced 
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by the phospholipase Cβ (PLCβ)-mediated cleavage of PIP2, a component of the plasma 
membrane that is ubiquitously dispersed across cell types (Aaltonen, Riera Ribas et al. 2014). SAG 
is thought to be the precursor molecule  for most of the 2-AG synthesized in the CNS as it is readily 
available and abundant in the CNS lipid membrane profile. 2-AG synthesis is stimulated by the 
activation of Gq/11 coupled metabotropic receptors, (metabotropic glutamate receptors mGluR 1 
and 5) and muscarinic acetylcholine receptors. The PLCβ-DAGLα pathway likely regulates ‘on 
demand’ synthesis of 2-AG due to there being a calcium requirement for PLCβ activity and both 
calcium influx and PLCβ activity results in increased eCB-mediated synaptic signaling (Ohno-
Shosaku, Maejima et al. 2001, Kim and Chouikha 2002, Ohno-Shosaku, Matsui et al. 2003, 
Fukudome, Ohno-Shosaku et al. 2004, Ramikie, Nyilas et al. 2014).  
Two diacylglycerol lipase isoforms (DAGL α and β) have been cloned and the 
characterization of the functional and regulation of these enzymes is ongoing. The α isoform has 
a longer C-terminal tail with multiple potential regulatory and scaffolding protein binding sites 
and is more abundantly expressed in the CNS.  (Bisogno et al. 2003, Jung et al. 2007, Oudin et al. 
2011). DAGLα is mostly found in mature neurons localized adjacent to CB1R expressing axon 
terminals. DAGLβ is expressed more broadly in peripheral tissues and visceral organs such as the 
liver (Bisogno, Howell et al. 2003, Katona, Urban et al. 2006, Yoshida, Uchigashima et al. 2011) 
(Uchigashima, Narushima et al. 2007).   
 DAGLα-/- mice have several stress and anxiety relevant phenotypes (Shonesy, Bluett et 
al. 2014, Shonesy, Bluett et al. 2014, Jenniches, Ternes et al. 2016, Patel, Shonesy et al. 2016) 
(Fig.1.6).  DAGLα-/- produce up to 80% less 2-AG in the CNS and exhibit grossly diminished 2-
AG signaling in the CNS. DAGLβ-/- mice show a 50% reduction in CNS 2-AG content do not 
have 2-AG mediated synaptic signaling deficiencies (Gao, Vasilyev et al. 2010) (Tanimura,  
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Yamazaki et al. 2010). Monoacylglycerol lipase (MAGL) hydrolyzes 87% of 2-AG to form 
arachidonic acid (Dinh, Carpenter et al. 2002, Blankman, Simon et al. 2007, Hoover, Blankman et 
al. 2008, Hermanson, Hartley et al. 2013). Two additional serine hydrolases, ABHD6 and 
ABHD12, account for a further 13% of 2- AG hydrolysis in rat brain membrane preparations 
(Blankman, Simon et al. 2007). MAGL inhibition results in  antidepressant and anxiolytic effects 
in mice, however as discussed in Chapter II, inhibition of MAGL 2 hours prior to fear extinction 
Figure 1.6. Comparison of anxiety and depression-like behaviors in two 
separate Dagl-/- mice. (-) not done, (NC) no change (Shonesy, Bluett et al. 
2014, Jenniches, Ternes et al. 2016). Figure adapted from (Shonesy, Bluett 
et al. 2014). 
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after auditory cue fear conditioning, resulted in a gross impairment of fear extinction (Fiskerstrand, 
H'Mida-Ben Brahim et al. 2010, Kinsey, O'Neal et al. 2011, Kinsey, Wise et al. 2013, Tchantchou 
and Zhang 2013,  Nomura, Morrison et al. 2011, Hartley, Gunduz-Cinar et al. 2016). Knockdown 
of MAGL in cultured cells enhances the accumulation of 2-AG following application of 
ionomycin, which stimulates the production of 2-AG by elevating intracellular Ca2+ (Dinh, 
Carpenter et al. 2002). DAGLα is expressed in the postsynaptic neuron and MAGL is co-expressed 
with CB1R in tightly regulated presynaptic microdomains to facilitate precise control over 
signaling and rapid hydrolysis (Gulyas, Cravatt et al. 2004). Whether this regulation is driven 
mainly to clear 2-AG from the synaptic terminal or in response to a demand for AA synthesis, 
remains unclear.  It is important to note that 2-AG was originally thought to have little function 
except as a an intermediate in the production of arachidonic acid (AA) (Prescott and Majerus 
1983). In this past decade 2-AG has been found to be an important regulator of the stress response. 
However it should not be overlooked that when 2-AG is hydrolyzed by MAGL to produce AA, 
AA also has important signaling capabilities in the presynaptic bouton. AA has been shown to 
mediate receptor expression, lipid trafficking, and calcium channel regulation (Dh, Sladek et al. 
1995, Horimoto, Nabekura et al. 1997, Fink, Lesage et al. 1998, Meves 2008, Yang, Zhang et al. 
2008, Pertwee 2015). Presynaptic AA activity related to outcomes of the following study are 
discussed in more detail in Chapter III.  It is likely that both 2-AG and AA signaling are important 
synaptic modulators. Both AEA and 2-AG signaling serve to modulate stress effects with 
downstream consequences for HPA axis activity and the capacity to return to homeostasis after 
exposure to stress.  In the following Chapter we have attempted to clarify how 2-AG synthesis and 
signaling mitigates fear extinction in mice using a auditory cue fear conditioning- fear extinction 
paradigm by inhibiting DAGL at key time points throughout the study.   
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Our overarching hypothesis is that DAGL regulates fear extinction learning in male and 
female mice following fear conditioning and is not a consequence of adaptations resulting from a 
genetic deficiency. Overall, our convergent pharmacological and genetic data demonstrate an 
important role for DAGL in the regulation of fear extinction and further suggest deficient 2-AG-
mediated eCB signaling may be an important susceptibility endophenotype that promotes the risk 
for the development of trauma-related psychiatric disorders.  
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Abstract 
Elucidating the underlying molecular mechanisms regulating fear and extinction learning 
may offer insights that can lead to novel treatments for debilitating anxiety and trauma-related 
disorders including posttraumatic stress disorder (PTSD). The endocannabinoid (eCB) system is a 
retrograde inhibitory signaling pathway involved in regulating central responses to stress. The eCB 
2-arachidonoylglycerol (2-AG) has recently been proposed to serve as a homeostatic signal 
mitigating adverse effects of stress exposure, however, less well understood is 2-AG’s role in fear 
learning and fear extinction. In this study, we have sought to explore 2-AG’s role in fear 
conditioning and fear extinction by disrupting 2-AG synthesis utilizing the DAGL inhibitor 
(DO34) and DAGLα knock-out mice (DAGLα-/-). We found that DAGLα-/- mice, and male and 
female C57B6/J mice treated with DO34, exhibited impairment in extinction learning in an 
auditory cue fear-conditioning paradigm. DO34 did not increase unconditioned freezing. 
Interestingly, inhibition of fatty-acid amide hydrolase (FAAH) was not able to restore normal fear 
extinction in DO34-treated mice suggesting increased Anandamide (AEA) cannot compensate for 
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deficient 2-AG signaling in the regulation of fear extinction. Moreover, augmentation of CB1R 
signaling with tetrahydrocannabinol (THC) also failed to restore normal fear extinction in DO34- 
treated mice. Overall, these data support the hypothesis that DAGLα plays an important role in 
fear extinction learning. Although genetic and pharmacological disruption of DAGL activity 
causes widespread lipidomic remodeling, these data combined with previous studies putatively 
suggest that deficient 2-AG signaling could be a susceptibility endophenotype for the development 
of trauma-related psychiatric disorders. 
 
Introduction 
Over the past 25 years, studies have shown that the endocannabinoid (eCB) system is a key 
regulator of an organism’s response to stress and plays an important role in facilitating recovery 
after exposure to stress (Lutz, Marsicano et al. 2015, Patel, Hill et al. 2017, Hill, Campolongo et 
al. 2018). Dysregulation of fear learning, fear extinction learning, and the abnormal retention of a 
heightened fear response have been implicated in many anxiety-related mental illnesses including 
posttraumatic stress disorder (PTSD) (Parsons and Ressler 2013, Maren and Holmes 2016, 
Deslauriers, Toth et al. 2017) . Understanding the molecular mechanisms involved in fear learning, 
fear extinction, and the development of generalized anxiety with persistent hyper responsiveness 
to stressful situations, could lead to important insights into the pathophysiological mechanisms 
underlying fear adaptations and potentially novel treatment approaches for stress-related mental 
disorders. In this study, we investigate the role of eCBs in fear learning and fear extinction via 
pharmacological and genetic modulation of 2-arachidonoylglycerol (2-AG) synthesis in male and 
female mice.  
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      The eCB system is a retrograde inhibitory signaling pathway composed of the 
presynaptic cannabinoid CB1 receptor (CB1R) and its endogenous ligands AEA 
(arachidonoylethanolamine) and 2-AG (Herkenham, Lynn et al. 1990, Matsuda, Lolait et al. 1990, 
Devane, Hanus et al. 1992, Piomelli 2003, Ohno-Shosaku and Kano 2014). 2-AG is the most 
abundant eCB in the brain and is acutely increased by stress exposure (Kondo, Kondo et al. 1998, 
Patel, Roelke et al. 2005, Patel, Kingsley et al. 2009, Dubreucq, Matias et al. 2012, Bedse, Hartley 
et al. 2017). It is hypothesized that this stress-induced increase in 2-AG signaling serves to 
counteract some of the adverse behavioral consequences of stress exposure (Hohmann, Suplita et 
al. 2005, Evanson, Tasker et al. 2010, Hill, McLaughlin et al. 2011, Wang, Hill et al. 2012, Bluett, 
Gamble-George et al. 2014, Bedse, Hartley et al. 2017, Bluett, Baldi et al. 2017). Conversely, AEA 
is decreased in response to stress, and plays a role in activating the stress response within the HPA-
axis (Dubreucq, Matias et al. 2012, McLaughlin, Hill et al. 2012, Wang, Hill et al. 2012, Gray, 
Vecchiarelli et al. 2015, Gray, Wilson et al. 2016). Studies have shown that augmenting 2-AG 
reduces stress-induced anxiety-like and depressive-like behaviors and can promote resilience to 
the adverse effects of acute and repeated stress (Kinsey, O'Neal et al. 2011, Sciolino, Zhou et al. 
2011, Sumislawski, Ramikie et al. 2011, Roberts, Stuhr et al. 2014, Zhang, Wang et al. 2015, 
Bedse, Hartley et al. 2017, Bluett, Baldi et al. 2017, Heinz, Genewsky et al. 2017). 2-AG 
augmentation can also increase active fear responses to threats (Heinz, Genewsky et al. 2017). 
Surprisingly, 2-AG augmentation promotes the expression of conditioned freezing and impairs 
conditioned fear extinction learning (Llorente-Berzal, Terzian et al. 2015, Hartley, Gunduz-Cinar 
et al. 2016). This surprising contradiction highlights the complexity of eCB signaling in the brain 
and motivated us to further investigate the role of 2-AG signaling in the regulation of fear learning 
and extinction.  
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      DAGLα is a key enzyme responsible for 2-AG synthesis in the postsynaptic neuron in 
response to increased synaptic activity (Bisogno, Howell et al. 2003, Tanimura, Yamazaki et al. 
2010, Shonesy, Bluett et al. 2014). Repeated homotypic stress results in increased 2-AG 
production via DAG hydrolysis by DAGLα (Patel, Kingsley et al. 2009). DAGLα-/- mouse models 
show reduced levels of 2-AG (and in some cases AEA (Tanimura, Yamazaki et al. 2010, Jenniches, 
Ternes et al. 2016)), increases in anxiety associated behaviors and increased susceptibility to 
adverse behavioral consequences of stress exposures (Shonesy, Bluett et al. 2014, Jenniches, 
Ternes et al. 2016, Bluett, Baldi et al. 2017). These studies are consistent with work demonstrating 
reducing 2-AG levels via MAGL overexpression also increases anxiety-like behaviors 
(Guggenhuber, Romo-Parra et al. 2015). In addition, acute treatment with the DAGL inhibitor 
DO34 increases innate anxiety levels and promotes susceptibility to the adverse behavioral 
consequences of stress in mice (Bedse, Hartley et al. 2017, Bluett, Baldi et al. 2017). Interestingly, 
DAGLα-/- also exhibit impairment in extinction of conditioned fear responses (Jenniches, Ternes 
et al. 2016). Here we aim to replicate and extend these findings to gain insight into how DAGL 
regulates fear extinction learning using a combination of pharmacological and genetic approaches 
in male and female mice. Overall, our convergent pharmacological and genetic data demonstrate 
an important role for DAGL in the regulation of fear extinction and further suggest deficient 2-
AG-mediated eCB signaling may be an important susceptibility endophenotype subserving risk 
for the development of trauma-related psychiatric disorders.  
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Results 
DAGLα-/- mice have impaired fear extinction 
Given that it has been previously shown that global DAGLα-/- mice exhibit impaired fear 
extinction (Jenniches, Ternes et al. 2016), we first aimed to replicate these findings in our line of 
global DAGLα-/- mice in a fear conditioning and extinction protocol we and others have 
previously utilized extensively (Hartley, Gunduz-Cinar et al. 2016) (Fig. 1a). There was no 
significant difference in freezing to tone during fear-conditioning on day 1 between DAGLα-/- and 
WT littermate controls (Fig. 1b-c). However, freezing behavior in response to tone presentation 
during extinction was increased in both male and female DAGLα-/- mice compared to WT 
littermate controls (Fig. 1b-c, Female day 2 and 3: p= 0.0154/0.0124, F(1,7) = 6.422/11.18, eta2= 
0.23/0.32, males day 2 and 3: (p= 0.0390/0.0261, F(1,7) = 10.13/7.901, h2 = 0.26/0.30). Freezing 
levels were also significantly higher during extinction recall in DAGLα-/- male and female mice 
compared to WT mice during both baseline and tone presentation (females day 4:p= 0.0389, F(1,7) 
= 6.431, h2 = 0.28, males day 4: p= 0.0045, F(1,7) = 16.87, eta2= 0.59).  
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Figure 2.1. Male and female DAGLa-/- mice have impaired fear extinction. (A) Schematic 
diagram of the experimental paradigm. (B) (Far left panel) % freezing by male DAGLa-/- 
and WT mice during acquisition of cue-conditioned fear. (Middle panels) % freezing during 
auditory cue during extinction training days 2 and 3. (Far right panel) % freezing during 
extinction recall (n=5 WT, n=4 KO mice) (C) (Far left panel) % freezing by female DAGLa-
/- and WT mice during acquisition of cue-conditioned fear. (Middle panels) % freezing 
during auditory cue during extinction training days 2 and 3. (Far right panel) % freezing 
during extinction recall (n=5 WT, n=4 KO mice). F, P and h2 values for genotype effect 
shown in each panel. All values are presented as mean ± SEM. 
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Pharmacological DAGL inhibition does not affect acquisition of conditioned-fear 
 
In order to confirm the effects observed in DAGLα-/- mice were mediated via impaired 
enzymatic activity during adulthood and to gain insight into the temporal regulation of fear 
learning and extinction by DAGL, we utilized a pharmacological inhibitor of DAGL, DO34 
(Ogasawara, Deng et al. 2016). We first tested whether acquisition of conditioned fear was 
regulated by DAGL activity via administration of DO34 or vehicle 2 hours prior to fear 
conditioning on day one in Context A (Fig. 2a). We observed a very small but significant decrease 
in freezing behavior in DO34-treated male mice compared to vehicle-treated controls during 
conditioning (Fig. 2b, day 1: p= 0.050, F(1,38) = 8.875, h2 = 0.025) suggesting a slight delay in 
the acquisition of conditioned freezing behavior. In contrast, there was no significant difference in 
subsequent freezing behavior during tone presentation during extinction training on days 2-3 nor 
during extinction recall on day 4 in the drug-free states.  
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Figure 2.2. Pharmacological DAGL inhibition does not affect acquisition of conditioned-fear. 
(A) Schematic diagram of the experimental paradigm. (B) (Far left panel) % freezing by 
C57BL/6 J male mice during acquisition of cue-conditioned fear when DO34 (50mg kg-1) 
was injected IP 2 hours prior to trial. (Middle panels) % freezing during auditory cue during 
extinction training days 2 and 3. (Far right panel) % freezing during extinction recall (n=20 
male mice per condition). F, P and h2 values for main effect of drug treatment show in each 
panel. All values are presented as mean ± SEM. 
 
Pharmacological DAGL inhibition impairs fear extinction 
 
Data derived from global DAGLα-/-  mice suggest a potential role for 2-AG signaling in 
the regulation of fear extinction; however, limitations of global knock-out models make conclusive 
interpretations in this regard difficult (Jenniches, Ternes et al. 2016). To circumvent these 
limitations, we next determined whether acute depletion of 2-AG using the pharmacological 
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DAGL inhibitor DO34 would also inhibit fear extinction learning in male and female mice (Fig. 
3a). We utilized a dose of 50 mg/kg which we have shown causes a near-complete elimination of 
measurable 2-AG throughout the brain (Bedse, Hartley et al. 2017, Bluett, Baldi et al. 2017). Prior 
to conditioning, mice were assigned to vehicle or DO34 treatment groups. There were no 
differences in freezing response to tone-sock pairings between groups (Fig. 3b), confirming similar 
conditioning efficiency in both treatment groups. On day two, DO34 or vehicle was injected 2 
hours prior to extinction training. DO34-treated male and female mice showed a significant 
increase in percent freezing time during tone presentation on both extinction day 2 and extinction 
day 3 (Fig. 3b-c Fig. 3b-c, day 2 and 3: female p= 0.0023/0.0006 F(1,38)= 10.69/14.13, h2 = 
0.097/0.142, male p= 0.0015/0.0023, F(1,33) = 11.96/10.93, eta2= 0.11/0.11) suggesting a slight 
delay). During the extinction recall test on day 4, performed under drug-free conditions, previously 
DO34-treated mice showed a sensitized freezing response during baseline and subsequent tone 
presentation relative to vehicle-treated mice Fig. 3b-c, day 4: female p=0.0005, F(1,36)= 14.5,   
h2= 0.195, male p= 0.0015, F(1,33) = 11.96, eta2= 0.11). Similar effects were observed in female 
mice (Fig. 3c). The effect of DO34 treatment during extinction training was similar to that 
observed in mice that did not undergo extinction training compared to those that did (Fig. S1 day 
4: p=0.0075, F(1,28)= 8.136, h2 = 0.166), indicating DAGL inhibition during extinction training 
reduces the effectiveness of fear extinction training, mirroring effects obtained in mice which had 
not undergone extinction training at all.   
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Figure 2.3. Pharmacological DAGL inhibition impairs fear extinction (A) Schematic 
diagram of the experimental paradigm. (B) (Far left panel) % freezing by C57BL/6 J male 
mice during acquisition of cue-conditioned fear. (Middle panels) % freezing during auditory 
cue by mice during extinction training days 2 and 3 when D034 (50mg kg-1) was injected IP 
2 hours prior to trial. (Far right panel) % freezing during extinction recall (n=17 DO34-
treated male mice, n=18 vehicle-treated male mice). (C) (Far left panel) % freezing by 
C57BL/6 J female mice during acquisition of cue-conditioned fear when DO34 (50mg kg-1) 
was injected IP 2 hours prior to trial. (Middle panels) % freezing during auditory cue during 
extinction training days 2 and 3. (Far right panel) % freezing during extinction recall (n=18 
DO34-treated female mice n=20 vehicle-treated female mice).  F, P and h2 values for main 
effects of drug treatment shown in each panel. All values are presented as mean ± SEM. 
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Figure 2.4. (S1) DO34 treatment prior to extinction training mimics the effect of no fear 
extinction training. (A) Schematic diagram of the experimental paradigm. (B) (Far left 
panel) % freezing by C57BL/6 J male mice during conditioning assay (Middle panels) % 
freezing during auditory cue during extinction training days 2 and 3. “No extinction” group 
remained in home cage during extinction trials day 2-3. (Far right panel) % freezing during 
extinction recall (n=15 male mice per condition). F, P and h2 values for main effect of 
condition (extinction vs. no extinction) shown in relevant panels. All values are presented as 
mean ± SEM. 
 
 
Pharmacological DAGL inhibition does not affect unconditioned freezing 
Given that DAGLα inhibition can increase unconditioned anxiety (Shonesy, Bluett et al. 
2014, Jenniches, Ternes et al. 2016), we wanted to rule out the possibility that DO34 increased 
freezing behavior independent of a fear-conditioning. To explicitly test this, mice were tested in a 
sham conditioning paradigm where, on day one in Context A, mice were exposed to tone without 
successive shocks (i.e. CS only) (Fig. 4a). On days 2-3 mice were injected with DO34 2 hours 
prior to sham fear extinction training. Freezing behavior was not different between DO34-treated 
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and vehicle-treated mice on days 2-3 of sham extinction, or on day 4 of sham extinction recall 
(Fig. 4b). These data indicate that DO34 does not increase freezing behavior independent of 
conditioning.  
 
 
 
Figure 2.5. Pharmacological DAGL inhibition does not affect unconditioned freezing. (A) 
Schematic diagram of the experimental paradigm. (B) (Far left panel) % freezing by 
C57BL/6 J male mice during sham-conditioning assay-no shock was administered after tone. 
(Middle panels) % freezing during auditory cue during extinction training days 2 and 3. (Far 
right panel) % freezing during extinction recall (n=15 male mice per condition). F and P 
values for main effect of drug treatment shown in each panel. All values are presented as 
mean ± SEM. 
 
 
AEA augmentation does not reverse impaired extinction after DAGL inhibition 
 
In order to determine whether augmentation of AEA signaling could compensate for 
deficient 2-AG synthesis and promote successful fear extinction, we blocked AEA degradation 
using the FAAH inhibitor PF-3845 concomitantly with DO34 treatment during extinction training 
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(Fig. 5a). We found no significant difference between the groups’ freezing behaviors when mice 
were given DO34 + FAAH Inhibitor or DO34 alone, prior to fear extinction training on days 2 or 
3 (Fig. 5b). 
 
 
 
Figure 2.6. AEA augmentation does not reverse impaired extinction after DAGL inhibition 
(A) Schematic diagram of the experimental paradigm. (B) (Far left panel) % freezing by 
C57BL/6 J male mice during acquisition of cue-conditioned fear. (Middle panels) % freezing 
during auditory cue by mice during extinction training days 2 and 3 when DO34 (50mg kg-
1) was injected alone or in addition to PF-3845 (FAHH inhibitor 1 mgkg-1) IP 2 hours prior 
to trial. (Far right panel) % freezing during extinction recall (n=18 male mice per condition). 
F, P and h2 values for main effect of drug shown in each panel. All values are presented as 
mean ± SEM. 
 
CB1R partial agonist THC does not reverse impaired extinction after DAGL inhibition 
In order to determine whether activation of CB1R receptors could compensate for deficient 
2-AG synthesis and promote successful fear extinction, we injected THC (0.3-0.6 mg/kg) 30 
minutes before extinction training on days 2 and 3. We found no significant difference between 
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the groups’ freezing behaviors when mice were given DO34 + THC or DO34 alone, prior to fear 
extinction training on days 2 or 3 (Fig. S2). 
 
 
 
Figure 2.7. (S2). THC does not reverse impaired extinction after DAGL inhibition (A) 
Schematic diagram of the experimental paradigm. (B) (Far left panel) % freezing by 
C57BL/6 J male mice during acquisition of cue-conditioned fear. (Middle panels) % freezing 
during auditory cue by mice during extinction training days 2 and 3 when DO34 (50mg kg-
1) was injected IP 2 hours prior to trial, alone or with an additional injection of THC 30 
minutes prior to extinction training (THC 0.6 mgkg-1) (Far right panel) % freezing during 
auditory cue during CS recall (n=14 DO34+THC-treated male mice, n=13 
DO34+vehicle=treated male mice, n=14 vehicle+vehicle-treated male mice). F and P and h2 
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values obtained by repeated measures two-way ANOVA representing effect of DAGL+THC 
treatment, DO34+vehicle treatment, and vehicle only treated animals, prior to fear 
extinction training. A separate ANOVA was conducted to compare DO34+THC and 
DO34+vehicle-treated animals, and is shown. Colored dots corresponding to treatment 
legend delineates which treatments are represented in each analysis. All values are given as 
mean ± SEM. (C) In a separate experiment there was no significant difference in total 
freezing behavior between two doses of THC (THC 0.3 and 0.6 mgkg-1) on extinction days 2 
and 3. Significance values obtained by student t-test of total freezing behavior during the 
entire trial. 
 
Discussion 
eCB signaling is a well-established regulator of fear extinction, however, the role of 2-AG 
in the regulation of these processes has only recently been studied due to previously limited 
pharmacological and genetic tools to interrogate 2-AG signaling in vivo (Llorente-Berzal, Terzian 
et al. 2015, Hartley, Gunduz-Cinar et al. 2016, Jenniches, Ternes et al. 2016). Generation of 
pharmacological tools for 2-AG augmentation and depletion (Ogasawara, Deng et al. 2016), and 
development of global and conditional DAGLα-/- mice (Shonesy, Bluett et al. 2014, Bluett, Baldi 
et al. 2017), has significantly enhanced our ability to examine the role of 2-AG within multiple 
stress-related biological processes. In this context, we aimed to utilize convergent pharmacological 
and genetic modulation of DAGL to elucidate the role of 2-AG signaling in fear-learning and 
extinction. The main findings of the present study are that 1) global life-long DAGLα deletion 
results in impaired extinction of conditioned fear, 2) acute pharmacological DAGL inhibition 
impairs extinction of conditioned fear behavior, and 3) Neither FAAH inhibition nor THC were 
able to correct these deficits in fear extinction caused by acute DAGL inhibition. These data 
provide further support for the notion that 2-AG deficiency states could predispose to the 
development of stress-related psychopathology and that pharmacological approaches aimed at 
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counteracting this deficiency could represent novel approaches to the treatment of an array of 
anxiety and trauma-related disorders (Bedse, Hartley et al. 2017, Bluett, Baldi et al. 2017, Hill, 
Campolongo et al. 2018).  
With regard to the effects of 2-AG modulation on acquisition of conditioned fear behaviors, 
our pharmacological data suggest 2-AG signaling may be important for aversive learning as DO34 
administered prior to conditioning slowed the acquisition of conditioned freezing behavior. This 
finding is consistent with data showing accelerated acquisition of conditioned freezing in a trace 
fear conditioning paradigm after 2-AG augmentation with the monoacylglycerol lipase (MAGL) 
inhibitor JZL184 (Xu, Antion et al. 2014). These data suggest 2-AG signaling may be important 
for optimal cognitive function consistent with the proposed nootropic effects of CB1 receptor 
stimulation in ageing (Bilkei-Gorzo, Albayram et al. 2017). However, cognitive impairment of 
CB1 stimulation have also been demonstrated (Kruk-Slomka, Dzik et al. 2017), suggesting a 
potentially complex and/or divergent roles of eCB signaling relative to exogenous cannabinoid 
agonist administration.  
Our findings that both genetic and pharmacological inhibition of DAGL impair fear 
extinction are consistent with a recent study showing impaired long-term fear extinction in 
DAGLα-/-  mice (Jenniches, Ternes et al. 2016). Our studies extend these findings by demonstrating 
impaired fear extinction after acute pharmacological DAGL inhibition, suggesting findings in 
DAGLα-/- mice are not a consequence of developmental abnormalities or compensatory 
adaptations resulting from life-long DAGLα deletion. We further show that the effects of DAGL 
inhibition are not confounded by increases in unconditioned freezing. Overall, these data are 
consistent with long-standing findings that blockade or genetic deletion of CB1 receptors robustly 
impairs fear extinction (see (Lutz 2007, Ruehle, Rey et al. 2012, Rabinak and Phan 2014, Hill, 
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Campolongo et al. 2018) for review), supporting the notion that 2-AG depletion secondary to 
DAGL inhibition may be the cause of the behavioral effects observed here. However, DAGL 
inhibition causes widespread changes in lipidomic networks and thus lack of ability to conclusively 
ascribe 2-AG deficiency as causally related to the observed phenotypes remains a limitation of the 
work. Lastly, extinction impairing effects of DO34 were only observed when relatively high shock 
intensities were used for the US (0.7 mA), but not lower (0.4 mA) intensities (data not shown). 
This caused significant fear generalization as evidence by unconditioned freezing during the 
baseline period in all mice on days 2, 3 and 4. Whether the effects of DAGL inhibition are 
explicitly dependent on US intensity remains to be determined.  
That acute pharmacological DAGL inhibition is associated with impaired extinction of 
conditioned fear is also globally consistent with the increased unconditioned anxiety and increased 
stress-susceptibility observed after DGAL inhibition and in DAGLα-/-  mice (Shonesy, Bluett et al. 
2014, Jenniches, Ternes et al. 2016, Bedse, Hartley et al. 2017, Bluett, Baldi et al. 2017). These 
data are also consistent with the anxiolytic effects of 2-AG augmentation in a variety of 
unconditioned anxiety models and the ability or 2-AG augmentation to reduce, and promote 
resilience to, the adverse effects of stress exposure (Busquets-Garcia, Puighermanal et al. 2011, 
Kinsey, O'Neal et al. 2011, Sciolino, Zhou et al. 2011, Sumislawski, Ramikie et al. 2011, Zhang, 
Wang et al. 2015, Morena, Leitl et al. 2016, Bluett, Baldi et al. 2017). Taken together, these recent 
and compelling findings suggest 2-AG is an important signaling molecule involved in reducing 
unconditioned anxiety and the adverse effects of stress, and facilitating appropriate extinction of 
aversive memories. They also suggest 2-AG deficiency could represent a susceptibility 
endophenotype predisposing to anxiety and trauma-related psychiatric disorders (see (Hill, 
Campolongo et al. 2018)). A corollary to these conclusions is that 2-AG augmentation may 
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represent a novel approach for the treatment of anxiety and stress-related neuropsychiatric 
disorders, however, there are some contradictory findings in this regard. Specifically, as noted 
above (Fig. 2), 2-AG augmentation increased the acquisition of conditioned fear responses, 
increased the expression of conditioned fear (Llorente-Berzal, Terzian et al. 2015), and impairs 
fear extinction (Hartley, Gunduz-Cinar et al. 2016). Thus, there appears to be an emerging 
distinction between the effects of 2-AG augmentation on conditioned versus unconditioned fear 
behaviors, with only the latter being consistently reduced in response to pharmacological 2-AG 
augmentation.  
A critical question that arises from these findings is how both augmenting and depletion of 
2-AG results in similar fear extinction deficits. The fear promoting effects of 2-AG augmentation 
are absent in mice with GABA neuron-specific CB1 deletion, supporting the importance of 2-AG 
acting on GABAergic neurons to impair extinction and promote conditioned fear (Llorente-Berzal, 
Terzian et al. 2015). The retrograde inhibition of GABA release may regulate important circuits 
within the basolateral amygdala thereby enhancing neuronal output to the central amygdala 
controlling freezing behavior. It is also important to point out that CB1 deletion from forebrain 
glutamatergic neurons itself impairs fear extinction (Llorente-Berzal, Terzian et al. 2015). Based 
on these data we propose the extinction-impairing and anxiogenic effects of 2-AG deficiency are 
due to reduced activity at CB1 on limbic glutamatergic terminals, which may be tonically 
suppressed by 2-AG signaling. In contrast, the fear promoting and extinction impairing effects of 
MAGL inhibition are mediated via 2-AG accumulation, synaptic spillover, and subsequent 
activation of CB1 on GABAergic neurons controlling freezing behavior. We hypothesize that these 
synapses may physiologically be under less tonic inhibition by 2-AG than glutamatergic CB1, thus 
2-AG depletion does not significantly change CB1 activity on GABAergic cells and does not 
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produce anxiolytic effects per se. A critical assumption in this model is the differential tonic 
inhibition of glutamate and GABA release mediated via 2-AG-CB1 signaling, an effect which 
remains to be tested experimentally. Additionally, that 2-AG augmentation reduces unconditioned 
anxiety suggests 2-AG may be acting on distinct neural circuits to affect excitation/inhibition 
balance to ultimately differentially affect conditioned versus unconditioned behaviors.  
With regard to the therapeutic potential of eCB signaling, pharmacological AEA 
augmentation via inhibition of FAAH has also been demonstrated to have anxiolytic and anti-
stress effects (Piomelli, Tarzia et al. 2006, Gunduz-Cinar, Hill et al. 2013, Hill, Campolongo et al. 
2018), and to facilitate extinction of conditioned fear in some models (Gunduz-Cinar, MacPherson 
et al. 2013, Llorente-Berzal, Terzian et al. 2015). Furthermore, we have recently demonstrated that 
FAAH inhibition can prevent the unconditioned anxiety associated with acute 2-AG depletion 
(Bedse, Hartley et al. 2017). However, FAAH inhibition at the same dose used in Bedse et al. was 
unable to enhance fear extinction in mice treated with DO34, suggesting AEA cannot compensate 
for all aspects of  DAGL inhibition. Furthermore, the addition of the CB1 partial agonist, THC 
was unable to overcome 2-AG-deficiency-induced impairments in fear extinction at  dose that has 
mitigated anxiety like behaviors in non-fear conditioning paradigms (Bedse, Hartley et al. 2017). 
In Bedse et al. when animals were treated with 0.3mg/kg dose of THC + 50mg/kg of DO34 they 
showed decreases in anxiety like behaviors versus animals treated with DO34 alone. In this study, 
we tested both 0.3 and 0.6mg/kg doses and found no significance between doses in total freezing 
behavior or the ability to reverse fear extinction impairments caused by DAGL inhibition. Whether 
direct full CB1 agonists or CB1 positive allosteric modulators, or alternative doses of THC, could 
overcome DAGL inhibition-induced impairments in fear extinction is a critical open question in 
the field of cannabinoid therapeutics development.  
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In summary, by utilizing genetic and pharmacological approaches, we have demonstrated 
a that DAGL activity plays an important role in fear extinction learning in both male and female 
mice. We have also shown that augmentation of AEA levels during fear extinction cannot reverse 
fear extinction deficits caused by disrupting the molecular mechanisms regulating 2-AG synthesis. 
Our data combined with data in previous studies highlights the intriguing paradoxical findings that 
both depletion and augmentation of 2-AG levels impairs fear extinction. There are some 
limitations to the present work that should be considered in the context of the above interpretations. 
For example, DAGL inhibition decreases levels of several monoacylglycerols in addition to 2-AG 
and reduces arachidonic acid levels (Shonesy, Bluett et al. 2014, Ogasawara, Deng et al. 2016), 
both of which could affect physiology and behavior independent of 2-AG-mediated eCB signaling. 
In addition, both genetic and pharmacological approaches utilized here are systemic, therefore the 
specific brain regions and circuits responsible for the behavioral effects of DAGL inhibition are 
not currently known. Despite these limitations, the present data provide a solid framework from 
which to test critical hypotheses regarding the potential therapeutic benefits of eCB modulating 
compounds on stress-related behavioral outcomes.  
 
Methods And Materials 
Animals  
9-12-week-old male and female C57BL/6 J were used as subjects (Jackson Laboratory, Bar 
Harbor, ME, USA). Male and female DAGLα-/- mice on a C57BL/6J background were bred in 
house as described previously and used in one experiment (Shonesy, Bluett et al. 2014, Bluett, 
Baldi et al. 2017). All mice were habituated for one week at Vanderbilt Murine Neurobehavior 
Core prior to behavior testing. Three to five mice were housed per cage in a temperature and 
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humidity controlled housing facility under a 12-h light/dark cycle, with access to food and water 
ad libitum. Behavior experiments were performed during dark cycle under red light. All studies 
were approved by the Vanderbilt University Animal Care and Use Committees, and were 
conducted in accordance with the National Institute of Health Guide for the Care and Use of 
Laboratory Animals. 
 
Drug Treatment 
Mice were given an intraperitoneal (IP) injection of DO34 (50mg/kg) synthesized as 
previously described (Ogasawara, Deng et al. 2016) dissolved in an 18:1:1 solution of saline, 
ethanol and kolliphor EL (Sigma Aldrich, St. Louis, MO, USA), or vehicle alone (18:1:1 solution 
of saline, ethanol and kolliphor EL) 2 hours prior to behavioral testing at a volume of 10 ml/kg. In 
one experiment, mice were treated with a combination of DO34 (50mg/kg) and PF-3845 (FAAH 
Inhibitor) at 1 mg/kg (A gift from Pfizer Central Research), via IP injection 2 hours prior to 
behavioral testing, or just DO34 (50mg/kg) alone. In two experiments, mice were treated with a 
combination of IP injection of DO34 (50mg/kg) 2 hours prior to extinction training and 
Tetrahydrocannabinol (THC; CB1R partial agonist) at 0.3 mg/kg (in one experiment) or 0.6mg/kg 
(Cayman Chemical Company-18:1:1 solution of saline, ethanol and kolliphor EL), via IP injection 
30 minutes prior to behavioral testing, or just DO34 (50mg/kg) alone. Doses utilized in this study 
were similar to those previously described in (Bedse, Hartley et al. 2017). 
 
Fear-Condition and Extinction Paradigm 
Freezing behavior  was measured using video analysis software (Video Freeze-Med 
Associates) during all of the fear conditioning and extinction trials exactly as described previously 
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(Hartley, Gunduz-Cinar et al. 2016). The mice were placed in an auxiliary room directly adjacent 
to the testing room and allowed to acclimate for 30 minutes prior to each trial under red light, with 
consistent temperature and humidity conditions between the auxiliary and trial room. At the end 
of each protocol, the mice were placed in their respective home cages in the auxiliary room and 
later returned to the housing facility. 
On testing day 1, the mice were placed in a square Plexiglas chamber (dimensions: 30.5 x 
24.1 x 21.0 cm) housed in a sound proofing box developed by Med. Associates. Context A consists 
of a bare metal grid floor, no insert along the walls, and no added scent. Baseline measurement 
were taken for 90 seconds. After the baseline, six 30 second tones - conditioned stimulus (CS), 
were played through a chamber wall mounted speaker, each tone was followed by followed by a 
2 second .70mA shock (unconditioned stimulus-US). There was a 30 second delay between each 
tone. All mice who failed to freeze at least 50% by final CS on conditioning day were removed 
from analysis except in figure 2 where effects of DO34 on conditioning per se were examined.  
On testing days 2 and 3, mice were placed in the conditioning chamber in Context B for 
extinction training. Context B has a smooth white plastic floor insert to cover the metal grid, as 
well as a curved plastic insert along the side and back walls made of the same white plastic material 
as the floor. The wall insert has perforations that align with the wall mounted speaker in order to 
ensure the sound quality of the (CS). Additionally, a paper towel soaked in vanilla extract was 
placed under the floor insert and grid as a novel olfactory queue, specific to Context B. A baseline 
measure of freezing behavior was recorded for 30s followed by a series of 20 30s tones with a 30s 
delay between each tone. No shock was administered during the extinction training.  
On day 4, the mice were put back in Context B for CS recall. No drug was administered 
prior to CS recall. Baseline measure was taken for 2.5 min followed by five 30s tones with a 30s 
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delay between each tone. A final measure of extinction recall was taken after the final tone for 2.5 
minutes.  
 
Statistical analysis 
The freezing data for each group was analyzed using a repeated measures two-way 
ANOVA factoring trial block (time) and drug treatment/or genotype. Total freezing time was 
entered as reported by the video analysis software. All statistical analyses were conducted using 
Prism Graphpad 7. P<0.05 was considered significant throughout. F and P values for significant 
effects of drug treatment or genotype can be found within figure panels. Effect size was calculated 
using formula for h2  to reflect the proportion of total variability in the freezing behavior that is 
accounted for by variation in genotypes or drug treatment during each trial (Tabachnick and Fidell 
2007). 
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CHAPTER III 
Discussion And Future Directions 
Discussion 
The data presented in Chapter II demonstrate a clear need for further research concerning 
the role of DAGL in fear extinction learning. Given that exposure therapy is modeled from fear 
extinction research and is the clinical standard of care for patients suffering from PTSD, better 
understanding of the molecular underpinnings that enhance or diminish the effects of the treatment 
may lead to  medications that enhance the process or intercede to stop normal post traumatic stress 
responses from becoming maladaptive. In this study we have confirmed that acute DAGL activity 
is an important factor in inhibitory learning that is required to suppress a conditioned response 
rather than a consequence of developmental adaptions due to deletion of the gene. The results of 
this study also gave rise to several questions about how 2-AG signaling might spatially and 
temporally regulate fear extinction in mice. In addition this study also calls into question if fear 
extinction learning can be further regulated down stream of CB1R activity.  Our main conclusions 
and hypothesis regarding these questions are discussed in the following section.  
Freezing responses were clearly CS dependent and not simple anxiety as result of the DO34 
treatment. In another experiment, data not shown, there were no significant differences when mice 
were conditioned to context rather than tone, and mice were injected with DO34 or vehicle 2 hours 
prior to context specific extinction training. This result is in contrast to the significant differences 
seen in fear extinction/freezing behavior exhibited by mice that were fear conditioned to context 
and treated with JZL184 prior to extinction training (Hartley, Gunduz-Cinar et al. 2016). Although 
in Hartley et al. the protocol used to context condition mice was longer (multiple days) and was 
done with the ICR strain as opposed to C57 mice, these results could indicate that the extinction 
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deficits seen with  2-AG augmentation versus 2-AG depletion are mediated by different neuronal 
circuits and/or molecular pathways. To further support the hypothesis that 2-AG augmentation 
affects circuits differently than 2-AG depletion, when mice were treated with JZl184 plus the 
CB1R antagonist Rimonabant, fear extinction deficits were reversed in both auditory cue 
(identical protocol/ICR mice) and context specific fear conditioning paradigms.  
In contrast to other studies showing anxiolytic effects of CB1R stimulation, two partial 
CB1R agonists did not reverse fear extinction learning deficits in this study (Piomelli, Tarzia et 
al. 2006, Gunduz-Cinar, Hill et al. 2013, Hill, Campolongo et al. 2018). Using a CB1R antagonist, 
Hartley et al. reversed fear extinction deficits mediated by increased 2-AG after both context and 
auditory cue fear conditioning (Hartley, Gunduz-Cinar et al. 2016). Taken together with the other 
contrasting data, our hypothesis to explain this phenomenon is necessarily theoretical and warrants 
further investigation. Given that MAGL is expressed in presynaptic invaginating GABAergic 
synapses in the BLA, and less in glutamatergic presynaptic terminals, we hypothesize that 
increases in 2-AG by MAGL inhibition would cause significant spillover and inhibition of 
GABAergic signaling. Fear extinction is dependent on specific inhibition of glutamatergic fear 
promoting neurons within the BLA, and GABA release during fear extinction would be vital 
for this suppression, (Fig. 3.1a). DAGL is thought have a short half-life, and 2-AG is known to 
be synthesized on demand (Di Marzo, Melck et al. 1998, Ogasawara, Deng et al. 2016). 
Unpublished data from this lab has shown that 24 hours after fear conditioning 2-AG levels are 
down from basal pre-fear conditioned levels in the brain. At first glance this data 
may seem counter intuitive given the fear extinction learning deficits revealed by our data when 
2-AG synthesis is blocked. However, these results may indicate that 2-AG and DAGL activity 
are increased as a consequence of the fear extinction paradigm and necessary for fear extinction 
 59 
to occur. Excitatory signals from the LA to fear neurons in the BLA may need CB1R retrograde 
signaling to dampen activity in order to augment GABAergic inhibition of that circuit. 2-AG 
signaling may have only short term effects on particular synapses that express higher levels of 
MAGL in the BLA, making rapid degradation of 2-AG more likely (Fig. 3.1b). Again, by 
inhibiting MAGL, GABA inhibition would be diminished and the net effect of increased fear 
signaling would be the same It is highly likely that given the complexity of amygdalar neural 
circuitry, that 2-AG synthesis, and DAGL is tightly regulated in both a spatial and temporal 
manner. 2-AG  augmentation my inhibit specific synapses not normally regulated by 2-AG at a 
particular time points, and result in similar behavioral deficits exhibited when 2-AG is depleted. 
Augmentation of CB1R during fear extinction without the capability to specificity target 
specific circuits, may have had the same effect as 2-AG augmentation and potentiated critical 
fear circuits. It is also possible that due to the fact that 2-AG is a full agonist of the CB1R, 
partial agonists are not capable of simulating the normal 2-AG signaling capacity. An 
experiment using a full CB1R agonist may offer insight to this question.   
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Figure 3.1. Theoretical models of fear neuron circuit regulation as a result of 2-AG 
augmentation [(a) MAGL inhibitor-JZL184] or depletion [(b)DAGL inhibitor-DO34]. 
Red lines indicate glutamatergic neurons and projections, blue lines indicate 
GABAergic neurons and projections. Green circles with plus signs indicate a synapse 
which is potentiated, yellow circles with a minus symbol indicates a synapse which is 
inhibited, and gray circles marked by the letter ‘N’ indicate synapses with a net neutral 
effect of 2-AG  depletion in figure (b). Dotted lines indicate a projection with a 
weakened signaling output as a result of 2-AG depletion (b).    
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       Injecting mice with JZL184 and inhibition the degradation of 2-AG by MAGL did not 
significantly affect fear conditioning. Injecting DO34 and inhibition the synthesis of 2-AG via  
DAGL, had a small but significant effect on fear conditioning. Mice given DO34 prior to 
conditioning had no significant difference in the percent of freezing behavior during the sixth 
conditioning CS/US stimulus. Neither JZL184 nor DO34 treatment administered before 
auditory-cue fear conditioning had any effect on subsequent ‘drug free’ fear extinction on days 
2-3 compared to vehicle controls. Mice in both experiments however, did exhibit freezing 
behavior to tone at the beginning of the extinction trials (Hartley, Gunduz-Cinar et al. 2016). 
These results indicate fear learning is not overtly dependent on 2-AG/CB1R signaling, and 
neither increases or decreases of 2-AG is important for fear learning and memory consolidation  
processes.  
One caveat to the data presented in Chapter II, continues to be somewhat puzzling. The 
lack of fear extinction deficit on days 2 and 3 when DO34 was administered prior to fear 
conditioning indicates that DO34 does not impair DAGL activity for more than 24 hours. A 
biochemical analysis measuring how long various DAGL inhibitors were able to decrease DAGL 
activity in brain tissue collected from mice injected with each molecule, showed that inhibiting 
DAGL activity with D034 resulted in an approximately 4 fold difference in DAGL activity 24 
hours after administration of the drug (Ogasawara, Deng et al. 2016). If  DAGL inhibition by 
DO34 knocks down DAGL expression/activity for 24 hours, we would have expected to there to 
be significant impairments on day 2 and 3 during fear extinction. The authors of this paper also 
contend that DAGL is a short half-life protein and that the duration of DAGL inhibition is a result 
of the drug remaining in the tissue for an extended period of time. One explanation for why we did 
not see extinction deficits on day 2-3 when mice were injected with DO34 prior to fear 
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conditioning is that DAGL may be rapidly trafficked to the synapse on demand in response to 
increases in synaptic activity. This increase may overcome the inhibitor after 24 hours and restore 
activity in response to acute stress. It is tempting to hypothesize that the inhibition of DAGL 
activity that causes deficits in fear extinction learning exhibited on day 4, can be compared to mice 
that had no day 2-3 extinction training. Given the lack of evidence showing restored DAGL activity 
mitigated by on demand synthesis, our data showing that fear extinction deficits and residual 
increased freezing behavior on CS recall day 4 (drug free) must be viewed with caution. It is 
possible that the impairment of fear extinction after DAGL inhibition is not mediated by 2-AG 
deficiency, but rather other mechanisms secondary to the widespread lipidomic changes induced 
by DAGL inhibition. 
Another explanation for our results showing that depletion of DAGL yields similar 
behavioral deficits to the augmentation of 2-AG  is downstream of CB1R activity. It cannot be 
ruled out that interruption of AA synthesis due to inhibition of either DAGL or MAGL regulates 
mechanisms involving fear extinction. Cyclooxygenase (COX) is an enzyme that facilitates the 
oxygenation of AA which in turn, produces prostaglandins (Marnett, Rowlinson et al. 1999). COX 
inhibitors, which would promote accumulation of AA in the presynaptic terminal secondary to 2-
AG signaling, have resulted in anxiolytic effects in mice during some behavioral tasks, with and 
without prior stress exposure, and disrupted contextual memory after fear conditioning (Hein, 
Stutzman et al. 2007, Hermanson, Hartley et al. 2013, Gamble-George, Baldi et al. 2016). These 
findings force  consideration that the downstream blockade of AA acid synthesis by either post 
synaptic DAGL and pre-synaptic MAGL inhibition, both ultimately result in a modest decrease of 
AA in the pre synaptic microdomain surrounding MAGL, within the axon terminal.  
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  CB1 receptors inhibit N-, P-, and Q-type calcium channels, activate inwardly rectifying 
potassium channels and block others in heterologous cells (Felder, Joyce et al. 1995, Pan, Ikeda et 
al. 1996, Glass, Dragunow et al. 1997, Pertwee 2015, Pertwee 2015). In contrast, AA has been 
shown to activate specific types of presynaptic potassium channels, increase synaptic vesicle 
fusion, and increase calcium channel currents, hypothetically counterbalancing or modulating the 
effect of CB1R activation (Dh, Sladek et al. 1995, Horimoto, Nabekura et al. 1997, Fink, Lesage 
et al. 1998, Huang, Woodruff et al. 2006, Meves 2008, Pertwee 2015). Inhibiting DAGL activity 
and blocking AA synthesis would not theoretically cause a change in net presynaptic activity given 
the CB1R is not activated in this paradigm. However, when MAGL is inhibited and CB1R activity 
is induced, the depletion of AA synthesis could result in sustained inhibition of the affected 
synaptic currents. BLA MAGL expression was found in presynaptic GABAergic terminals that 
also expressed CB1R and post synaptic DAGL which seemed to be absent in glutamatergic 
synapses (Yoshida, Uchigashima et al. 2011). As stated in Chapter II, we suspect  2-AG 
accumulation and synaptic spillover enhances subsequent activation of CB1 on GABAergic 
neurons controlling freezing behavior. In theory, AA acid depletion resulting from MAGL 
inhibition, may block counteracting AA activity and result in CB1R hyperactivity in BLA 
GABAergic synapses. This could account for the increased freezing behavior during fear 
extinction training observed by Hartley et al. 2016 when MAGL was inhibited by JZL184 (Hartley, 
Gunduz-Cinar et al. 2016).  
 We doubt the effects of AA are a major contributing factor in fear extinction learning 
deficits observed with administration of DAGL or MAGL inhibitors as 2-AG induces a CB1R-
dependent suppression of COX-2 activity and expression (Yang, Zhang et al. 2008). It is also 
possible that AA activity is important for aspects of fear extinction independent of calcium and 
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potassium channels and is not important for dampening CB1R signaling. An experiment testing 
fear extinction using a COX inhibitor with or without a CB1R antagonist could give us insight to 
the role of AA in fear extinction and whether or not CB1R activity mediates this response.  
 
Future Directions 
The open question concerning how DAGL activity and subsequent production of 2-AG 
specifically regulates fear extinction can be further explored using several different approaches. 
Understanding the spatial and temporal regulation of 2-AG following acute stress is needed in 
order to narrow down specific circuits for intervention. Based on prior work looking at 2AG level 
changes in response to stress, combined with finding that acute disruption of DAGL activity by 
DO34 injections prior to fear conditioning and extinction training leads to probable learning 
deficits and short term anxiety-related behavior, we hypothesize that there will be measurable 
differences in DAGL activity within specific brain regions and at specific time points during the 
fear conditioning and fear extinction paradigm. In order to test DAGL activity, a synthetic DAGL 
substrate (MRJ-20) fitted with a FRET pair on the N and C terminals of the substrate can be utilized 
to measure DAGL activity in homogenized brain tissue before and after each experimental trial in 
a FRET plate assay. Florescence will increase in proportion to substrate cleavage by DAGL. 
Micro- dissected brain regions including the amygdala, BNST, hippocampus, and mPFC at 
specific key time points during training and extinction should give an indication of where DAGL 
activity is increased or decreased in response to the conditioning and extinction paradigm. Given 
that DAGL is expressed at various levels across the brain structures we have targeted, we will also 
need to run western blots in order to measure the expression of DAGL within these brain regions 
samples to gather a rough estimate of protein expression so that it can be correlated with DAGL 
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activity. To measure 2-AG abundance, this lab has collected micro-dissected brain regions to be 
processed and analyzed via mass spectrometry at similar time points. From this data we will learn 
which brain regions have significant changes in DAGL activity in response to fear conditioning 
and in multiple stages of fear extinction. We will learn if DAGL activity and expression is 
increased during fear extinction learning, and if DAGL activity correlates with changes in freezing 
behavior. We can also test DAGL activity post DO34 treatments by intervals to understand how 
long DAGL activity is suppressed through DO34 inhibition.  
Once we determine the specific brain regions where 2-AG signaling is important for fear 
learning and extinction, we can confirm these results with titrated micro infusions of both DAGL 
inhibitors and CB1R agonist/antagonists to learn how CB1R activity regulates particular regions 
important for fear learning and extinction training. Using this technique we could add on GABAR 
agonists/antagonists to confirm that fear extinction learning is dependent on inhibition of specific 
regional signals with in the brain. This data would offer insight not only to eCB signaling during 
fear learning and extinction but also the unique signaling patterns of potentiation and inhibition 
after fear learning that promote fear extinction in mice. Physicians have started using Deep Brain 
Stimulation in some patients with severe PTSD to relieve his or her symptoms, and this data may 
offer guidance into how fear signaling patterns are disrupted in patients with PTSD. 
Experimentally, this data will narrow down the possible circuits to target for further study in order 
to better understand how fear learning and fear extinction are regulated. Electrophysiology 
techniques can then be utilized to study specific circuits and synaptic behaviors related to stress, 
fear learning/extinction regulation by eCB retrograde signaling.  
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Conclusion 
 In order to understand enhanced fear retention and how post traumatic stress becomes 
maladaptive, we must have a deeper understanding of the normal regulation involved in fear 
expression and extinction. Once the brain region, circuit level and molecular regulation of fear 
learning and extinction is well understood, we can start elucidate maladaptive patterns and study 
factors that promote resilience to trauma at a molecular level.  
Insight into the normal neural fear conditioning and fear extinction processes will identify 
potential targets for novel treatments for this debilitating anxiety/stress disorders, such as PTSD, 
as well as suggest interventions to prevent others from developing the disorder after trauma. 
Clearly the mammalian brain has evolved to enable an intricate fear learning network to facilitate 
fine discrimination between stimuli in a complex environment. The benefits of learning how these 
processes  are regulated have implications for the prevention of suffering on an enormous scale. 
Understanding the molecular underpinning of fear learning and extinction could lead to treatment 
and prevention breakthroughs that may alleviate economic and societal burdens due to PTSD, 
boost economic recovery and potential for those recovering from war-torn and developing 
countries, prevent long term underachievement by those who experience trauma, and offer relief 
to those who have sacrificed mental stability and health in the service of our country. Current 
estimates show that up to 70.4-89.7% of people will experience some form of trauma in their 
lifetime with an average of 3.4 traumas per person (Kilpatrick, Resnick et al. 2013, Kessler, 
Aguilar-Gaxiola et al. 2017). Of those approximately 10% will develop some degree of PTSD 
(Breslau 2009).  Research involving fear learning and fear extinction as a model for understanding 
complex fear adaptation has broad applications and is crucially important.
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